<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy - Dodd, JM - 2019 | Cochrane Library</title> <meta content="Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy - Dodd, JM - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012024.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy - Dodd, JM - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012024.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012024.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy" name="citation_title"/> <meta content="Jodie M Dodd" name="citation_author"/> <meta content="The University of Adelaide, Women's and Children's Hospital" name="citation_author_institution"/> <meta content="jodie.dodd@adelaide.edu.au" name="citation_author_email"/> <meta content="Rosalie M Grivell" name="citation_author"/> <meta content="Flinders University and Flinders Medical Centre" name="citation_author_institution"/> <meta content="Cecelia M OBrien" name="citation_author"/> <meta content="Robinson Research Institute, The University of Adelaide" name="citation_author_institution"/> <meta content="Therese Dowswell" name="citation_author"/> <meta content="The University of Liverpool" name="citation_author_institution"/> <meta content="Andrea R Deussen" name="citation_author"/> <meta content="The University of Adelaide, Women's and Children's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012024.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/11/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012024.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012024.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012024.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Gestational Age; Infant, Premature; Injections, Intramuscular; Perinatal Mortality; Pregnancy, High‐Risk; Pregnancy, Multiple; Premature Birth [*prevention &amp; control]; Progestins [administration &amp; dosage, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012024.pub3&amp;doi=10.1002/14651858.CD012024.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012024\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012024\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ko","th","ms","fa","pt"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012024.pub3",title:"Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy",firstPublishedDate:"Nov 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012024.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012024.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012024.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012024.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012024.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012024.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012024.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012024.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012024.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012024.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4968 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012024.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0189"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0085"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-sec-0183"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/appendices#CD012024-sec-0194"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/table_n/CD012024StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/table_n/CD012024StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#CD012024-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jodie M Dodd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#CD012024-cr-0003">Rosalie M Grivell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#CD012024-cr-0004">Cecelia M OBrien</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#CD012024-cr-0005">Therese Dowswell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information#CD012024-cr-0006">Andrea R Deussen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information/en#CD012024-sec-0198">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 November 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012024.pub3">https://doi.org/10.1002/14651858.CD012024.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012024-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012024-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012024-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012024-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012024-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012024-abs-0013">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012024-abs-0003">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012024-abs-0001" lang="en"> <section id="CD012024-sec-0001"> <h3 class="title" id="CD012024-sec-0001">Background</h3> <p>Multiple pregnancy is a strong risk factor for preterm birth, and more than 50% of women with a twin pregnancy will give birth prior to 37 weeks' gestation. Infants born preterm are recognised to be at increased risk of many adverse health outcomes, contributing to more than half of overall perinatal mortality. Progesterone is produced naturally in the body and has a role in maintaining pregnancy, although it is not clear whether administering progestogens to women with multiple pregnancy at high risk of early birth is effective and safe. </p> <p>Since publication of this new review in Issue 10, 2017, we have now moved one study (<a href="http://El-Refaie 2016" target="_blank">El‐Refaie 2016</a>) from included to studies awaiting classification, pending clarification about the study data. </p> </section> <section id="CD012024-sec-0002"> <h3 class="title" id="CD012024-sec-0002">Objectives</h3> <p>To assess the benefits and harms of progesterone administration for the prevention of preterm birth in women with a multiple pregnancy. </p> </section> <section id="CD012024-sec-0003"> <h3 class="title" id="CD012024-sec-0003">Search methods</h3> <p>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (1 November 2016) and reference lists of retrieved studies. </p> </section> <section id="CD012024-sec-0004"> <h3 class="title" id="CD012024-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials examining the administration of a progestogen by any route for the prevention of preterm birth in women with multiple pregnancy. We did not include quasi‐randomised or cross‐over studies. </p> </section> <section id="CD012024-sec-0005"> <h3 class="title" id="CD012024-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed reports identified by the search for eligibility, extracted data, assessed risk of bias and graded the quality of the evidence. </p> </section> <section id="CD012024-sec-0006"> <h3 class="title" id="CD012024-sec-0006">Main results</h3> <p>We included 16 trials, which all compared either vaginal or intramuscular (IM) progesterone with a placebo or no treatment, and involved a total of 4548 women. The risk of bias for the majority of included studies was low, with the exception of three studies that had inadequate blinding, or significant loss to follow‐up or both, or were not reported well enough for us to make a judgement. We graded the evidence <i>low</i> to <i>high</i> quality, with downgrading for statistical heterogeneity, design limitations in some of the studies contributing data, and imprecision of the effect estimate. </p> <p><b>1 IM progesterone versus no treatment or placebo</b> </p> <p>More women delivered <b>at less than 34 weeks' gestation</b> in the IM progesterone group compared with placebo (risk ratio (RR) 1.54, 95% confidence interval (CI) 1.06 to 2.26; women = 399; studies = 2; <i>low‐quality evidence</i>). Although the incidence of <b>perinatal death</b> in the progesterone group was higher, there was considerable uncertainty around the effect estimate and high heterogeneity between studies (average RR 1.45, 95% CI 0.60 to 3.51; infants = 3089; studies = 6; I<sup>2</sup> = 71%; <i>low‐quality evidence</i>). No studies reported <b>maternal mortality</b> or <b>major neurodevelopmental disability at childhood follow‐up</b>. </p> <p>There were no clear group differences found in any of the other maternal or infant outcomes (<b>preterm birth less than 37 weeks</b> (RR 1.05, 95% CI 0.98 to 1.13; women = 2010; studies = 5; <i>high‐quality evidence</i>); <b>preterm birth less than 28 weeks</b> (RR 1.08, 95% CI 0.75 to 1.55; women = 1920; studies = 5; <i>moderate‐quality evidence</i>); <b>infant birthweight less than 2500 g</b> (RR 0.99, 95% CI 0.90 to 1.08; infants = 4071; studies = 5; I<sup>2</sup> = 76%, <i>moderate‐quality evidence</i>)). No childhood outcomes were reported in the trials. </p> <p><b>2 Vaginal progesterone versus no treatment or placebo by dose</b> </p> <p>There were no clear group differences in incidence of <b>preterm birth before 34 weeks</b> (average RR 0.90, 95% CI 0.66 to 1.23; women = 1503; studies = 5; I<sup>2</sup> = 36%; <i>low‐quality evidence</i>). Although fewer births before 34 weeks appeared to occur in the progesterone group, the CIs crossed the line of no effect. Incidence of <b>perinatal death</b> was higher in the progesterone group, although there was considerable uncertainty in the effect estimate and the quality of the evidence was low for this outcome (RR 1.23, 95% CI 0.74 to 2.06; infants = 2287; studies = 3; <i>low‐quality evidence</i>). No studies reported <b>maternal mortality</b> or <b>major neurodevelopmental disability at childhood follow‐up</b>. </p> <p>There were no clear group differences found in any of the other maternal or infant outcomes (<b>preterm birth less than 37 weeks</b> (average RR 0.97, 95% CI 0.89 to 1.06; women = 1597; studies = 6; <i>moderate‐quality evidence</i>); <b>preterm birth less than 28 weeks</b> (RR 1.53, 95% CI 0.79 to 2.97; women = 1345; studies = 3; <i>low‐quality evidence</i>); <b>infant birthweight less than 2500 g</b> (average RR 0.95, 95% CI 0.84 to 1.07; infants = 2640; studies = 3; I<sup>2</sup> = 66%, <i>moderate‐quality evidence</i>)). No childhood outcomes were reported in the trials. </p> <p>For secondary outcomes, there were no clear group differences found in any of the other maternal outcomes except for <b>caesarean section</b>, where women who received vaginal progesterone did not have as many caesarean sections as those in the placebo group, although the difference between groups was not large (8%) (RR 0.92, 95% CI 0.86 to 0.98; women = 1919; studies = 5; I<sup>2</sup> = 0%). There were no clear group differences found in any of the infant outcomes except for <b>mechanical ventilation</b>, which was required by fewer infants whose mothers had received the vaginal progesterone (RR 0.70, 95% CI 0.52 to 0.94; infants = 2695; studies = 4). </p> </section> <section id="CD012024-sec-0007"> <h3 class="title" id="CD012024-sec-0007">Authors' conclusions</h3> <p>Overall, for women with a multiple pregnancy, the administration of progesterone (either IM or vaginal) does not appear to be associated with a reduction in risk of preterm birth or improved neonatal outcomes. </p> <p>Future research could focus on a comprehensive individual participant data meta‐analysis including all of the available data relating to both IM and vaginal progesterone administration in women with a multiple pregnancy, before considering the need to conduct trials in subgroups of high‐risk women (for example, women with a multiple pregnancy and a short cervical length identified on ultrasound). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012024-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012024-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012024-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012024-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012024-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012024-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012024-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012024-abs-0014">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD012024-abs-0009">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012024-abs-0006" lang="en"> <h3>Prenatal progestogens for preventing preterm birth in women with a multiple pregnancy</h3> <p><b>What is the issue?</b> </p> <p>More than half of women with a twin pregnancy give birth before the 37th week of pregnancy (preterm), and women expecting triplets are even more likely to have a preterm birth. Infants born preterm are more likely to die or have health problems compared with babies born at term. Progesterone is produced naturally in the body and is thought to help to maintain pregnancy. </p> <p>Since publication of this new review in Issue 10, 2017, we have now moved one study (<a href="http://El-Refaie 2016" target="_blank">El‐Refaie 2016</a>) from included to studies awaiting classification, pending clarification about the study data. </p> <p><b>Why is this important?</b> </p> <p>It is not known whether giving progesterone (by injection, orally or by vaginal suppositories or gels) to women with multiple pregnancy during pregnancy is beneficial or harmful to the woman and her babies. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence on 1 November 2016 and identified 16 randomised controlled trials involving 4548 women for inclusion in the review. </p> <p>In studies where women received progesterone by injection into the muscle compared with placebo (dummy treatment) more women gave birth before the 34th week of pregnancy in the progesterone group (<i>low‐quality evidence</i> ). There was no clear difference between the groups in the likelihood of the baby dying before or soon after the birth (<i>low‐quality evidence</i> ). No studies reported whether any women died or whether any babies had longer‐term developmental problems or disability. There seems to be little or no difference between women receiving progesterone or placebo for other important outcomes, such as preterm birth before 37 weeks (<i>high‐quality evidence</i> ); preterm birth before 28 weeks (<i>moderate‐quality evidence</i> ) or infant birthweight less than 2500 grams (<i>moderate‐quality evidence</i>). No childhood outcomes were reported in the trials. </p> <p>In studies where women received vaginal progesterone there may be little or no difference between women receiving progesterone or placebo in preterm birth before 34 weeks (<i>low‐quality evidence</i> ); although fewer births before 34 weeks occurred in the progesterone group, this finding may have occurred by chance. The number of infant deaths before or soon after birth was similar in both groups (<i>low‐quality evidence</i> ). No studies reported maternal death or longer‐term outcomes for babies. There may be little or no difference between groups receiving vaginal progesterone versus placebo in any other important outcomes (preterm birth before 37 weeks (<i>moderate‐quality evidence</i> ); preterm birth before 28 weeks (<i>low‐quality evidence</i> ); or infant birthweight less than 2500 grams (<i>moderate‐quality evidence</i>)). No childhood outcomes were reported in the trials. For other outcomes, we found no clear group differences, except for caesarean section where women who received vaginal progesterone did not have as many caesarean sections as those in the placebo group (although the difference between groups was not large (8%)). Fewer infants whose mothers had received the vaginal progesterone needed mechanical help with breathing. </p> <p>We did not find any studies looking at progesterone taken by mouth.</p> <p><b>What does this mean?</b> </p> <p>Overall, for women with a multiple pregnancy, treatment with progesterone (either intramuscular or vaginal) does not appear to reduce the likelihood of preterm birth or improve outcomes for babies. </p> <p>Future research could focus on looking at information about individual women taking part in studies, so that everything available about both intramuscular and vaginal progesterone treatments in women with a multiple pregnancy can be considered together. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012024-sec-0189" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012024-sec-0189"></div> <h3 class="title" id="CD012024-sec-0190">Implications for practice</h3> <section id="CD012024-sec-0190"> <p>Overall, for women with a multiple pregnancy, the administration of progesterone (either intramuscular or vaginal) does not appear to be associated with a reduction in risk of preterm birth or improved neonatal outcomes. </p> </section> <h3 class="title" id="CD012024-sec-0191">Implications for research</h3> <section id="CD012024-sec-0191"> <p>Future research could focus on a comprehensive individual participant data meta‐analysis including all of the available data relating to both intramuscular and vaginal progesterone administration in women with a multiple pregnancy, before considering the need to conduct specific trials in subgroups of high‐risk women (for example, women with a multiple pregnancy and a short cervical length identified on ultrasound). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012024-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012024-sec-0036"></div> <div class="table" id="CD012024-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: W</b> omen with a multiple pregnancy<br/> <b>Setting:</b> Obstetric clinics in Finland, France, Lebanon, the Netherlands, and the USA<br/> <b>Intervention:</b> Intramuscular (IM) progesterone<br/> <b>Comparison:</b> No treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intramuscular (IM) progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.60 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3089<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (20 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 34 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54<br/> (1.06 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/> (204 to 436) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability at childhood follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trial reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infant birthweight less than 2500 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.90 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4071<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000<br/> (558 to 669) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 28 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/> (0.75 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1920<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (43 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 37 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.98 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>614 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1000<br/> (602 to 688) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Statistical heterogeneity (I<sup>2</sup> &gt; 60%). Variation in size and direction of effect (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect. (‐1).<br/> <sup>3</sup>Study with design limitations (lack of blinding) contributing data (64.2% weight) (‐1).<br/> <sup>4</sup>Wide confidence interval (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012024-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women with a multiple pregnancy<br/> <b>Setting:</b> Obstetric clinics in Austria, Brazil, Canada, Denmark, Egypt, Spain, Turkey and UK<br/> <b>Intervention:</b> Vaginal progesterone<br/> <b>Comparison:</b> No treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vaginal progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.74 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2287<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (17 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 34 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.66 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1503<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (119 to 222) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability at childhood follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trial reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infant birthweight less than 2500 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.84 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2640<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1000<br/> (480 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 37 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.89 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1597<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1000<br/> (503 to 598) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 28 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.53<br/> (0.79 to 2.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1345<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (18 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>One study contributing data with design limitations (weight of 52.1%) (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>Two studies contributing data with design limitations (combined weight 47.9%) (‐1).<br/> <sup>4</sup> Downgraded due to concerns relating to inconsistency ‐ evidence of statistical heterogeneity with an I‐squared value of 66% (‐1).<br/> <sup>5</sup>One study contributing data with design limitations (weight of 33.9%) (‐1).<br/> <sup>6</sup>Most of the pooled effect was provided by studies with design limitations (‐1). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012024-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012024-sec-0037"></div> <section id="CD012024-sec-0038"> <h3 class="title" id="CD012024-sec-0038">Description of the condition</h3> <p>The rates of multiple pregnancies that occur naturally vary in different maternal age and ethnic groups; however, since the early 1980s the development of assisted reproduction techniques have led to a large increase in multiple births in high‐resource settings (<a href="./references#CD012024-bbs2-0070" title="CollinsJ . Global epidemiology of multiple birth. Reproductive Biomedicine Online2007;15 Suppl 3:45‐52. ">Collins 2007</a>; <a href="./references#CD012024-bbs2-0109" title="UmstadMP , HaleL , WangYA , SullivanEA . Multiple deliveries: the reduced impact of in vitro fertilisation in Australia. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2013;53(2):158‐64. ">Umstad 2013</a>). For example, in the 1980s in England and Wales twin pregnancies accounted for approximately 0.9% of births, but by the late 1990s this had increased to 1.4% (<a href="./references#CD012024-bbs2-0104" title="SmithLK , ManktelowBN , DraperES , BoyleEM , JohnsonSJ , FieldDJ . Trends in the incidence and mortality of multiple births by socioeconomic deprivation and maternal age in England: population‐based cohort study. BMJ Open2014;4:e004514. ">Smith 2014</a>). In Australia in 2010, multiple births accounted for 3.1% of all births (<a href="./references#CD012024-bbs2-0109" title="UmstadMP , HaleL , WangYA , SullivanEA . Multiple deliveries: the reduced impact of in vitro fertilisation in Australia. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2013;53(2):158‐64. ">Umstad 2013</a>). These trends have been reflected in many settings across the globe, although in many countries recent policies to restrict the number of embryos transferred during assisted conception may reverse this upward trend (<a href="./references#CD012024-bbs2-0070" title="CollinsJ . Global epidemiology of multiple birth. Reproductive Biomedicine Online2007;15 Suppl 3:45‐52. ">Collins 2007</a>; <a href="./references#CD012024-bbs2-0109" title="UmstadMP , HaleL , WangYA , SullivanEA . Multiple deliveries: the reduced impact of in vitro fertilisation in Australia. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2013;53(2):158‐64. ">Umstad 2013</a>). </p> <p>Multiple pregnancy is a strong risk factor for preterm birth. A woman with a multiple pregnancy is likely to have an over‐distended uterus in addition to any other risk factors which may occur in women with a singleton pregnancy. The risk of early birth before 37 weeks for women with a singleton pregnancy is 7.5% compared with 100% for women with a triplet pregnancy (<a href="./references#CD012024-bbs2-0064" title="AIHW2014 . Australia's Health 2014. Australia's Health Series no. 14. Cat. no. AUS 178. Canberra: AIHW, 2014. ">AIHW 2014</a>). More than 50% of women with a twin pregnancy will give birth prior to 37 weeks' gestation (<a href="./references#CD012024-bbs2-0064" title="AIHW2014 . Australia's Health 2014. Australia's Health Series no. 14. Cat. no. AUS 178. Canberra: AIHW, 2014. ">AIHW 2014</a>). </p> <p>Infants born preterm are recognised to be at increased risk of many adverse health outcomes, contributing to more than 50% of overall perinatal mortality (<a href="./references#CD012024-bbs2-0063" title="AustralianI of H , W . Australia's Mothers and Babies 2000. National Perinatal Statistics Unit, 2003. ">AIHW 2003</a>), as well as being at greater risk of dying in their first year of life (<a href="./references#CD012024-bbs2-0088" title="MartinJA , HamiltonBE , OstermanMJK . Births: Final data for 2013. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics, 2015; Vol. 64, issue 1:1‐30. ">Martin 2015</a>). For those preterm infants who initially survive the neonatal period, there is an increased risk of death during childhood due to increased risks of infection and other illnesses (<a href="./references#CD012024-bbs2-0066" title="BlencoweH , CousensS , ChouD , OestergaardM , SayL , MollerA , et al. Born too soon: the global epidemiology of 15 million preterm births. Reproductive Health2013;10 Suppl 1:S2. ">Blencowe 2013</a>; <a href="./references#CD012024-bbs2-0084" title="HowsonCP , KinneyMV , McDougallL , LawnJE , Born Too Soon Preterm Birth Action Group. Born too soon: preterm birth matters. Reproductive Health2013;10 Suppl 1:S1. ">Howson 2013</a>). In addition, infants born preterm are at increased risk of repeated admission to hospital (<a href="./references#CD012024-bbs2-0074" title="ElderDE , HagaR , EvansSF , BenningerHR , FrenchNP . Hospital admissions in the first year of life in very preterm infants. Journal of Paediatrics and Child Health1999;35(2):145‐50. ">Elder 1999</a>) and adverse outcomes, including blindness, hearing impairment, chronic lung disease, cerebral palsy and long‐term disability (<a href="./references#CD012024-bbs2-0066" title="BlencoweH , CousensS , ChouD , OestergaardM , SayL , MollerA , et al. Born too soon: the global epidemiology of 15 million preterm births. Reproductive Health2013;10 Suppl 1:S2. ">Blencowe 2013</a>; <a href="./references#CD012024-bbs2-0079" title="HackM . Consideration of the use of health status, functional outcome, and quality‐of‐life to monitor neonatal intensive care practice. Pediatrics1999;103(1 Suppl E):319‐28. ">Hack 1999</a>; <a href="./references#CD012024-bbs2-0106" title="StanleyF . Survival and cerebral palsy in low birthweight infants: implications for perinatal care. Paediatric and Perinatal Epidemiology1992;6(2):298‐310. ">Stanley 1992</a>), creating a significant burden upon the community (<a href="./references#CD012024-bbs2-0089" title="McCormickMC , LittJS , SmithVC , ZupancicJA . Prematurity: an overview and public health implications. Annual Review of Public Health2011;32:367‐79. ">McCormick 2011</a>). Even accounting for gestational age at birth, infants of a twin pregnancy are at greater risk of complications relating to prematurity than are singleton infants born at the same gestation. For example, the risk of cerebral palsy in all pregnancies is approximately 2/1000, but for twins this increases to 9/1000 and to 31/1000 for triplets (<a href="./references#CD012024-bbs2-0068" title="BromerJG , AtaB , SeliM , LockwoodCJ , SeliE . Preterm deliveries that result from multiple pregnancies associated with assisted reproductive technologies in the USA: a cost analysis. Current Opinion in Obstetrics &amp; Gynecology2011;23(3):168‐73. ">Bromer 2011</a>). </p> </section> <section id="CD012024-sec-0039"> <h3 class="title" id="CD012024-sec-0039">Description of the intervention</h3> <p>Progestogens are a group of hormones that act by binding to and activating the progesterone receptor, and are described as naturally occurring or synthetic agents (<a href="./references#CD012024-bbs2-0101" title="SchindlerAE , CampagnoliC , DruckmannR , HuberJ , PasqualiniJR , SchweppeKW , et al. Classification and pharmacology of progestins. Maturitas2008;61(1‐2):171‐80. ">Schindler 2008</a>). Progesterone and its metabolite, 17‐hydroxyprogesterone, is naturally occurring, and is produced by the body during pregnancy in high concentrations (<a href="./references#CD012024-bbs2-0075" title="FeghaliM , VenkataramananR , CaritisS . Prevention of preterm delivery with 17‐hydroxyprogesterone caproate: pharmacologic considerations. Seminars in Perinatology2014;48:516‐22. ">Feghali 2014</a>). In contrast, 17‐hydroxyprogesterone caproate is a synthetic progestin that is protein‐bound and lipophilic, and requires metabolism by the liver (<a href="./references#CD012024-bbs2-0075" title="FeghaliM , VenkataramananR , CaritisS . Prevention of preterm delivery with 17‐hydroxyprogesterone caproate: pharmacologic considerations. Seminars in Perinatology2014;48:516‐22. ">Feghali 2014</a>). The metabolites of 17‐hydroxyprogesterone caproate also differ from those of both progesterone and 17‐hydroxyprogesterone (<a href="./references#CD012024-bbs2-0075" title="FeghaliM , VenkataramananR , CaritisS . Prevention of preterm delivery with 17‐hydroxyprogesterone caproate: pharmacologic considerations. Seminars in Perinatology2014;48:516‐22. ">Feghali 2014</a>). </p> <p>Progestogen compounds may be administered in various forms and by various routes, with different formulations and mode of administration affecting absorption and therefore conferring potentially different bio‐effects (<a href="./references#CD012024-bbs2-0075" title="FeghaliM , VenkataramananR , CaritisS . Prevention of preterm delivery with 17‐hydroxyprogesterone caproate: pharmacologic considerations. Seminars in Perinatology2014;48:516‐22. ">Feghali 2014</a>). For example, 17‐hydroxyprogesterone caproate is administered by intramuscular injection, and has a half‐life of 16 days, with the drug remaining detectable several weeks after intramuscular injection (<a href="./references#CD012024-bbs2-0069" title="CaritisSN , SharmaS , VenkataramananR , HankinsGD , MiodovnikM , HebertMF , et al. Pharmacology and placental transport of 17‐hydroxyprogesterone caproate in singleton gestation. American Journal of Obstetrics and Gynecology2012;207(5):398.e1‐398.e8. ">Caritis 2012</a>). In contrast, progesterone, when administered orally, undergoes significant first‐pass metabolism within the liver, although vaginal administration reduces this effect, with a half‐life of the order of 16 to 18 hours (<a href="./references#CD012024-bbs2-0105" title="StanczykFZ , HapgoodJP , WinerS , MishellDRJr . Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Reviews2013;34(2):171‐208. [10.1210/er.2012‐1008. Epub 2012 Dec 13] ">Stanczyk 2013</a>). </p> <p>A number of case‐control studies have not identified an increased risk of congenital anomalies following the use of natural progesterone (<a href="./references#CD012024-bbs2-0095" title="Raman‐WilmsL , TsengAL , WighardtS , EinarsonTR , KorenG . Fetal genital effects of first‐trimester sex hormone exposure: a meta‐analysis. Obstetrics and Gynecology1995;85(1):141‐9. ">Raman‐Wilms 1995</a>; <a href="./references#CD012024-bbs2-0100" title="SchardeinJ . Congenital abnormalities and hormones. Teratology1980;22:251. ">Schardein 1980</a>), or 17‐hydroxyprogesterone caproate (<a href="./references#CD012024-bbs2-0092" title="MichaelisJ , MichaelisH , GluckE , KollerS . Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology1983;27(1):57‐64. ">Michaelis 1983</a>; <a href="./references#CD012024-bbs2-0096" title="ResseguieLJ , HickJF , BruenJA , NollerKL , O׳FallonWM , KurlandLT . Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936–1974. Fertility and Sterility1985;43(4):514–9. ">Resseguie 1985</a>; <a href="./references#CD012024-bbs2-0110" title="VarmaTR , MorsmanJ . Evaluation of the use of Proluton‐Depot (hydroxyprogesterone hexanoate) in early pregnancy. International Journal of Gynaecology and Obstetrics1882;20(1):13‐7. ">Varma 1982</a>) in pregnancy. However, a large population‐based study evaluating the use of progesterone prior to conception indicates an association with some childhood cancers (<a href="./references#CD012024-bbs2-0082" title="HargreaveM , JensenA , NielsenTS , ColovEP , AndersenKK , PinborgA , et al. Maternal use of fertility drugs and risk of cancer in children‐‐a nationwide population‐based cohort study in Denmark. International Journal of Cancer2015;136(8):1931‐9. ">Hargreave 2015</a>). </p> <p>Maternal side‐effects from progesterone therapy include headache, breast tenderness, nausea, cough and local irritation if administered intramuscularly. At present, there is little information available about the optimal dose of progesterone, mode of administration, gestational age at which to begin therapy, or duration of therapy (<a href="./references#CD012024-bbs2-0078" title="GreeneMF . Progesterone and preterm delivery ‐ deja vu all over again. New England Medical Journal2003;348(24):2453‐5. ">Greene 2003</a>; <a href="./references#CD012024-bbs2-0085" title="IamsJD . Supplemental progesterone to prevent preterm birth. American Journal Obstetrics and Gynecology2003;188(2):303. ">Iams 2003</a>). </p> </section> <section id="CD012024-sec-0040"> <h3 class="title" id="CD012024-sec-0040">How the intervention might work</h3> <p>Progesterone has a role in maintaining pregnancy (<a href="./references#CD012024-bbs2-0080" title="HaluskaGJ , CookMJ , NovyMJ . Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. American Journal of Obstetrics and Gynecology1997;176(3):682‐91. ">Haluska 1997</a>; <a href="./references#CD012024-bbs2-0093" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Peiber 2001</a>; <a href="./references#CD012024-bbs2-0094" title="PepeGJ , AlbrechtED . Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocrine Review1995;16(5):608‐48. ">Pepe 1995</a>), and is thought to act by suppressing smooth muscle activity in the uterus (<a href="./references#CD012024-bbs2-0065" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD012024-bbs2-0077" title="GrazziniE , GuillonG , MouillacB , ZinggHH . Inhibition of oxytocin receptor function by direct binding of progesterone. Nature1998;392(6675):509‐12. ">Grazzini 1998</a>). In many animal species, there is a reduction in the amount of circulating progesterone before the onset of labour. While these changes have not been shown to occur in women (<a href="./references#CD012024-bbs2-0065" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD012024-bbs2-0067" title="BlockBS , LigginsGC , CreasyRK . Preterm delivery is not predicted by serial plasma estradiol or progesterone concentration measurements. American Journal of Obstetrics and Gynecology1984;150(6):716‐22. ">Block 1984</a>; <a href="./references#CD012024-bbs2-0087" title="Lopez‐BernalA . Mechanism of labour ‐ biochemical aspects. BJOG: an international journal of obstetrics and gynaecology2003;110(Suppl 20):39‐45. ">Lopez‐Bernal 2003</a>; <a href="./references#CD012024-bbs2-0093" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Peiber 2001</a>; <a href="./references#CD012024-bbs2-0103" title="SmitDA , EssedGG , deHaanJ . Predictive value of uterine contractility and the serum levels of progesterone and oestrogens with regard to preterm labour. Gynecologic and Obstetric Investigation1984;18(5):252‐63. ">Smit 1984</a>), it has been suggested that there is a 'functional' withdrawal of progesterone related to changes in the expression of progesterone receptors in the uterus (<a href="./references#CD012024-bbs2-0065" title="AstleS , SlaterDM , ThorntonS . The involvement of progesterone in the onset of human labour. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2003;108(2):177‐81. ">Astle 2003</a>; <a href="./references#CD012024-bbs2-0072" title="CondonJC , JeyasuriaP , FaustJM , WilsonJW , MendelsonCR . A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proceedings of the National Academy of Sciences of the United States of America2003;100(16):9518‐23. ">Condon 2003</a>; <a href="./references#CD012024-bbs2-0081" title="HaluskaGJ , WellsTR , HirstJJ , BrennerRM , SadowskyDW , NovyMJ . Progesterone receptor localisation and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition. Journal of the Society for Gynecological Investigation2002;9(3):125‐36. ">Haluska 2002</a>; <a href="./references#CD012024-bbs2-0093" title="PeiberD , AllportVC , HillsF , JohnsonM , BennettPR . Interactions between progesterone receptor isoforms in myometrial cells in human labour. Molecular Human Reproduction2001;7(9):875‐9. ">Peiber 2001</a>). There have been relatively recent reports in the literature advocating the use of progesterone to reduce the risk of preterm birth (<a href="./references#CD012024-bbs2-0073" title="DaFonsecaEB , BittarRE , CarvalhoMH , ZugaibM . Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2003;188(2):419‐24. ">Da Fonseca 2003</a>; <a href="./references#CD012024-bbs2-0091" title="MeisPJ , KlebanoffM , ThomE , DombrowskiMP , SibaiB , MoawadAH , et al. Prevention of recurrent preterm delivery by 17 alpha‐hydroxyprogesterone caproate. New England Journal of Medicine2003;348(24):2379‐85. ">Meis 2003a</a>), rekindling interest that dates back to the 1960s (<a href="./references#CD012024-bbs2-0086" title="LeVineL . Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgical Obstetrics and Gynecology1964;72:30‐6. ">Le Vine 1964</a>), although no progestogen deficiency state has been described in women delivering preterm, either with singletons or multiple pregnancy. </p> </section> <section id="CD012024-sec-0041"> <h3 class="title" id="CD012024-sec-0041">Why it is important to do this review</h3> <p>Preterm birth and its consequences for women and their babies is a significant health problem in pregnancy and childbirth. While the suppression or prevention of preterm labour should lead to improved survival through a lower incidence of premature birth, there are theoretical reasons why a fetus may not survive without disability. It is possible that an intrauterine mechanism that would trigger preterm labour could also cause neurological injury to the fetus and that progesterone may prevent labour, but not fetal injury. The purpose of this review is to assess the benefits and harms of progesterone administration for the prevention of preterm birth for both women and their infants, when considering the risk factors present for preterm birth. </p> <p>An existing Cochrane Review examined the prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth (<a href="./references#CD012024-bbs2-0113" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a>). This review included women considered at high risk because of multiple pregnancy, as well as women with singleton pregnancies considered at high risk for various clinical reasons (history of preterm birth, short cervix, threatened preterm labour and other risk factors). The review included 36 trials, with several trials recruiting only women with multiple pregnancies. Results of the review may be easier to interpret and more clinically relevant if the results for women with multiple and singleton pregnancy are assessed and reported separately. Consequently, the review has been divided into two reviews, with this review focusing on women with a multiple pregnancy and the other examining the effects of progesterone in women with singleton pregnancies considered to be at high risk of preterm birth. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012024-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012024-sec-0042"></div> <p>To assess the benefits and harms of progesterone administration for the prevention of preterm birth in women with a multiple pregnancy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012024-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012024-sec-0043"></div> <section id="CD012024-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012024-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included all published and unpublished randomised controlled trials (including those using a cluster‐randomised design), in which a progestogen was administered for the prevention of preterm birth in women with multiple pregnancies. We included studies published as abstracts or brief reports, provided there was sufficient information available to assess risks of bias. </p> <p>Trials were excluded if:</p> <p> <ol id="CD012024-list-0001"> <li> <p>a quasi‐randomised methodology or cross‐over design was used;</p> </li> <li> <p>a progestogen was administered for the acute treatment of actual or threatened preterm labour (that is, where progesterone was administered as an acute tocolytic medication); or </p> </li> <li> <p>a progestogen was administered in the first trimester of pregnancy only for preventing miscarriage. </p> </li> </ol> </p> </section> <section id="CD012024-sec-0046"> <h4 class="title">Types of participants</h4> <p>Pregnant women considered to be at increased risk of preterm birth because of a multiple pregnancy. Women with multiple pregnancy may also have additional risk factors such as short cervix, and we have included studies which include women with multiple risk factors. </p> <p>We planned to include studies which recruited women with either a singleton or multiple pregnancy who were considered to be at high risk of preterm birth for other obstetric reasons, provided that randomisation was stratified by plurality of the pregnancy and that findings for women with multiple pregnancies were reported separately, or could be obtained from trial authors. </p> </section> <section id="CD012024-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Administration of a progestogen by any route (intravenous (IV), intramuscular (IM), oral or vaginal) for the prevention of preterm birth compared with placebo or no treatment. Where data were available, we have presented results separately according to route of administration, as progestogens administered by different routes may have a different effect. </p> </section> <section id="CD012024-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD012024-sec-0049"> <h5 class="title">Primary outcomes</h5> <section id="CD012024-sec-0050"> <h6 class="title">Maternal</h6> <p> <ol id="CD012024-list-0002"> <li> <p>Maternal mortality</p> </li> <li> <p>Preterm birth (less than 34 weeks' gestation)</p> </li> </ol> </p> </section> <section id="CD012024-sec-0051"> <h6 class="title">Infant</h6> <p> <ol id="CD012024-list-0003"> <li> <p>Perinatal mortality</p> </li> <li> <p>Major neurodevelopmental disability at childhood follow‐up</p> </li> </ol> </p> </section> </section> <section id="CD012024-sec-0052"> <h5 class="title">Secondary outcomes</h5> <section id="CD012024-sec-0053"> <h6 class="title">Maternal</h6> <p> <ol id="CD012024-list-0004"> <li> <p>Preterm birth less than 37 weeks</p> </li> <li> <p>Preterm birth less than 28 weeks</p> </li> <li> <p>Mean gestational age at birth</p> </li> <li> <p>Threatened preterm labour (as defined by trial authors)</p> </li> <li> <p>Prelabour spontaneous rupture of membranes</p> </li> <li> <p>Adverse drug reaction</p> </li> <li> <p>Pregnancy prolongation (interval between randomisation and birth)</p> </li> <li> <p>Mode of birth</p> </li> <li> <p>Number of antenatal hospital admissions</p> </li> <li> <p>Satisfaction with the therapy</p> </li> <li> <p>Use of tocolysis</p> </li> <li> <p>Maternal infection</p> </li> <li> <p>Antenatal corticosteroids</p> </li> <li> <p>Maternal quality of life</p> </li> </ol> </p> </section> <section id="CD012024-sec-0054"> <h6 class="title">Infant</h6> <p> <ol id="CD012024-list-0005"> <li> <p>Birthweight less than the third centile for gestational age</p> </li> <li> <p>Birthweight less than 2500 g</p> </li> <li> <p>Mean birthweight</p> </li> <li> <p>Apgar score of less than seven at five minutes</p> </li> <li> <p>Respiratory distress syndrome</p> </li> <li> <p>Use of mechanical ventilation</p> </li> <li> <p>Duration of mechanical ventilation</p> </li> <li> <p>Intraventricular haemorrhage ‐ grades III or IV</p> </li> <li> <p>Periventricular leucomalacia</p> </li> <li> <p>Retinopathy of prematurity</p> </li> <li> <p>Retinopathy of prematurity ‐ grades III or IV</p> </li> <li> <p>Chronic lung disease</p> </li> <li> <p>Necrotising enterocolitis</p> </li> <li> <p>Neonatal sepsis</p> </li> <li> <p>Fetal death</p> </li> <li> <p>Neonatal death</p> </li> <li> <p>Admission to neonatal intensive care unit</p> </li> <li> <p>Neonatal length of hospital stay</p> </li> <li> <p>Teratogenic effects (including virilisation in female infants)</p> </li> <li> <p>Patent ductus arteriosus</p> </li> </ol> </p> </section> <section id="CD012024-sec-0055"> <h6 class="title">Child</h6> <p> <ol id="CD012024-list-0006"> <li> <p>Major sensorineural disability (defined as any of legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy, or developmental delay or intellectual impairment (defined as developmental quotient or intelligence quotient less than ‐2 standard deviations below mean)) </p> </li> <li> <p>Developmental delay (however defined by the authors)</p> </li> <li> <p>Intellectual impairment</p> </li> <li> <p>Motor impairment</p> </li> <li> <p>Visual impairment</p> </li> <li> <p>Blindness</p> </li> <li> <p>Deafness</p> </li> <li> <p>Hearing impairment</p> </li> <li> <p>Cerebral palsy</p> </li> <li> <p>Child behaviour</p> </li> <li> <p>Child temperament</p> </li> <li> <p>Learning difficulties</p> </li> <li> <p>Growth assessments at childhood follow‐up (weight, head circumference, length, skin‐fold thickness) </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD012024-sec-0056"> <h3 class="title">Search methods for identification of studies</h3> <p>The following Methods section of this protocol is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD012024-sec-0057"> <h4 class="title">Electronic searches</h4> <p>We searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (1 November 2016). </p> <p>The Register is a database containing over 22,000 reports of controlled trials in the field of pregnancy and childbirth. For full search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this link to the editorial information about the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html" target="_blank">Cochrane Pregnancy and Childbirth</a> in the Cochrane Library and select the ‘<b><i>Specialized Register</i> </b> ’ section from the options on the left side of the screen. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD012024-list-0007"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Two people screen the search results and review the full text of all relevant trial reports identified through the searching activities described above. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set which has been fully accounted for in the relevant review sections (<a href="./references#CD012024-bbs1-0001" title="">Included studies</a>; <a href="./references#CD012024-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD012024-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD012024-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (1 November 2016) for unpublished, planned and ongoing trial reports using the search methods in <a href="./appendices#CD012024-sec-0195">Appendix 1</a>. </p> </section> <section id="CD012024-sec-0058"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions.</p> </section> </section> <section id="CD012024-sec-0059"> <h3 class="title" id="CD012024-sec-0059">Data collection and analysis</h3> <p>The following Methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD012024-sec-0060"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently assessed for inclusion all the studies we identified as a result of the search strategy. We resolved any disagreement through discussion or consulted a third review author. </p> <p>We created a study flow diagram to map out the number of records identified, included and excluded (see Figure 1). </p> </section> <section id="CD012024-sec-0061"> <h4 class="title">Data extraction and management</h4> <p>We designed a form to extract the data, used by two review authors for eligible studies. We resolved discrepancies through discussion or, if required, consulted a third member of the review team. We entered data into Review Manager 5 software (<a href="./references#CD012024-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and checked them for accuracy. When information regarding any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD012024-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risks of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012024-bbs2-0083" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving a third assessor. </p> <section id="CD012024-sec-0063"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>For each included study we assessed the method as being at:</p> <p> <ul id="CD012024-list-0008"> <li> <p>low risk of bias (any truly random process, e.g. random number table; computer random‐number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0064"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>For each included study we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD012024-list-0009"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively‐numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes; alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0065"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>For each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding was unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD012024-list-0010"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for personnel.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0066"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>For each included study we described the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as being at:</p> <p> <ul id="CD012024-list-0011"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0067"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>For each included study, and for each outcome or class of outcomes, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we planned to re‐include missing data in the analyses that we undertook. </p> <p>We assessed methods as being at:</p> <p> <ul id="CD012024-list-0012"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; ‘as treated’ analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0068"> <h5 class="title">(5) Selective reporting (checking for reporting bias)</h5> <p>For each included study we described how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as being at:</p> <p> <ul id="CD012024-list-0013"> <li> <p>low risk of bias (where it was clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0069"> <h5 class="title">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</h5> <p>For each included study we described any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias: </p> <p> <ul id="CD012024-list-0014"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear whether there is risk of other bias.</p> </li> </ul> </p> </section> <section id="CD012024-sec-0070"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012024-bbs2-0083" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we planned to assess the likely magnitude and direction of the bias and whether we considered it was likely to have an impact on the findings. In future updates, we will explore the impact of the level of bias through undertaking sensitivity analyses (<a href="#CD012024-sec-0084">Sensitivity analysis</a>). </p> </section> <section id="CD012024-sec-0071"> <h5 class="title">Assessment of the quality of the evidence using GRADE</h5> <p>We assessed the overall quality of the evidence using the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a> for the main comparison: administration of progesterone by any route for the prevention of preterm birth compared with placebo or no treatment. </p> <p>We assessed the quality of the evidence for the following outcomes:</p> <p> <ol id="CD012024-list-0015"> <li> <p>Perinatal mortality</p> </li> <li> <p>Preterm birth (less than 34 weeks' gestation)</p> </li> <li> <p>Major neurodevelopmental disability at childhood follow‐up</p> </li> <li> <p>Infant birthweight less than 2500 g</p> </li> <li> <p>Preterm birth less than 37 weeks</p> </li> <li> <p>Preterm birth less than 28 weeks</p> </li> </ol> </p> <p>We used the <a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool to import data from Review Manager 5 (<a href="https://archie.cochrane.org/sections/documents/view?version=z1504230930157165546616659907507%26format=REVMAN#REF-RevMan-2014" target="_blank">RevMan 2014</a>) in order to create ’Summary of findings’ tables. We produced a summary of the intervention effect and a measure of quality for each of the above outcomes using GRADE methodology. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments of risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> </section> </section> <section id="CD012024-sec-0072"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012024-sec-0073"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we present results as a summary risk ratio (RR) with a 95% confidence interval (CI). </p> </section> <section id="CD012024-sec-0074"> <h5 class="title">Continuous data</h5> <p>For continuous data, we have used the mean difference (MD) if outcomes were measured in the same way between trials. We planned to use the standardised mean difference (SMD) to combine trials that measure the same outcome, but use different methods. </p> </section> </section> <section id="CD012024-sec-0075"> <h4 class="title">Unit of analysis issues</h4> <section id="CD012024-sec-0076"> <h5 class="title">Cluster‐randomised trials</h5> <p>There were no cluster‐randomised trials identified during the search. In future updates of this review, we will include cluster‐randomised trials in the analyses along with individually‐randomised trials. We plan to adjust their sample sizes using the methods described in the <i>Handbook</i> using an estimate of the intracluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and we consider the interaction between the effect of intervention and the choice of randomisation unit to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> </section> <section id="CD012024-sec-0077"> <h5 class="title">Multiple pregnancy</h5> <p>Special methods are needed when carrying out analysis of outcomes for babies from multiple pregnancies (<a href="./references#CD012024-bbs2-0076" title="GatesS , BrocklehurstP . How should randomised trials including multiple pregnancies be analysed?. BJOG: an international journal of obstetrics and gynaecology2004;111(3):213‐9. ">Gates 2004</a>). Outcomes in babies from multiple pregnancies are not independent. For many outcomes there will be a higher correlation between babies from the same pregnancy than between babies from different pregnancies. The degree of non‐independence of outcomes for babies from multiple pregnancies will vary considerably, depending on the outcome and the type of multiple pregnancy; for some outcomes an adverse event in one twin will almost invariably be associated with the same event in the other (e.g. preterm birth); for other outcomes the degree of correlation will be lower (e.g. fetal death), but still higher than for babies from different pregnancies. In view of this non‐independence, we treated babies from the same pregnancy as clusters and adjusted the data. We planned to obtain ICCs from the trials, or use ICCs from similar studies. However, published ICCs for multiple pregnancies were not available. We therefore estimated ICCs (based on clinical knowledge and data from observational studies) and carried out sensitivity analysis. We tested the effect of using two extremes of ICC. The first assumed complete dependence between twin infants; effectively we divided the number of events and the sample size by two (i.e. to reduce the sample size to the number of women rather than the number of infants). A second sensitivity analysis imagined a very low rate of dependence (1%) between twins; for this analysis we adjusted the events and sample sizes by dividing each by 1.01. </p> </section> <section id="CD012024-sec-0078"> <h5 class="title">Cross‐over trials</h5> <p>Cross‐over trials are not a suitable design for this type of intervention and have not been included. </p> </section> </section> <section id="CD012024-sec-0079"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we have noted levels of attrition. If sufficient data had been available, we would have explored the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis. </p> <p>For all outcomes, we carried out analyses, as far as possible, on an intention‐to‐treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and analysed all participants in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing. </p> </section> <section id="CD012024-sec-0080"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau<sup>2</sup>, I<sup>2</sup> and Chi<sup>2</sup> statistics. We regarded heterogeneity as substantial if the I<sup>2</sup> was greater than 30% and either the Tau<sup>2</sup> was greater than zero, or there was a low P value (less than 0.10) in the Chi<sup>2</sup> test for heterogeneity. </p> </section> <section id="CD012024-sec-0081"> <h4 class="title">Assessment of reporting biases</h4> <p>In future updates, if there are 10 or more studies in the meta‐analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will seek statistical advice on further analysis. We will also report whether the trial was prospectively registered and check that outcomes in the trial registration and subsequent publications are the same. </p> </section> <section id="CD012024-sec-0082"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (<a href="./references#CD012024-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect, i.e. where trials were examining the same intervention, and we judged the trials’ populations and methods to be sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we found substantial statistical heterogeneity, we used random‐effects meta‐analysis to produce an overall summary, if we considered an average treatment effect across trials clinically meaningful. We treated the random‐effects summary as the average of the range of possible treatment effects and we have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. </p> <p>Where we used random‐effects analyses, the results are presented as the average treatment effect with a 95% confidence interval, and the estimates of Tau<sup>2</sup> and I<sup>2</sup>. </p> </section> <section id="CD012024-sec-0083"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where we identified substantial heterogeneity, we investigated it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, used random‐effects analysis to produce it. </p> <p>We carried out, where possible, the following subgroup analyses:</p> <p> <ol id="CD012024-list-0016"> <li> <p>Time of treatment beginning (before 20 weeks' gestation versus after 20 weeks' gestation)</p> </li> <li> <p>Different dosage regimens (divided arbitrarily into a cumulative dose of less than 500 mg per week versus a dose greater than or equal to 500 mg per week) </p> </li> </ol> </p> <p>We used the following outcomes, where possible, in subgroup analysis:</p> <p> <ol id="CD012024-list-0017"> <li> <p>Perinatal mortality</p> </li> <li> <p>Preterm birth (less than 34 weeks' gestation)</p> </li> <li> <p>Major neurodevelopmental disability at childhood follow‐up</p> </li> </ol> </p> <p>We assessed subgroup differences by interaction tests available within Review Manager 5 (<a href="./references#CD012024-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We reported the results of subgroup analyses quoting the Chi<sup>2</sup> statistic and P value, and the interaction test I<sup>2</sup> value. </p> </section> <section id="CD012024-sec-0084"> <h4 class="title">Sensitivity analysis</h4> <p>For perinatal death we carried out sensitivity analysis by testing the effect of using two extremes of ICC. The first assumed complete dependence between twin infants; effectively we divided all events and the sample size by two to reduce the sample size to the number of women rather than the number of infants. A second sensitivity analysis assumed a very low rate of dependence (1%) between twins; for this analysis we adjusted the events and sample sizes by dividing each by 1.01. </p> <p>For our primary outcomes we planned to carry out sensitivity analysis examining the impact of risk of bias on results; studies that were at high risk of bias due to high sample attrition (&gt; 20% at childhood follow‐up) were to be temporarily excluded from the analysis. Where we have conducted this sensitivity analysis, we have reported the result in the text for our primary analysis in Comparison 1. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012024-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012024-sec-0085"></div> <section id="CD012024-sec-0086"> <h3 class="title">Description of studies</h3> <section id="CD012024-sec-0087"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD012024-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012024-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Our search strategy identified 61 studies for consideration (some studies published multiple reports). We include 16 randomised trials in this review (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>). We excluded 33 studies, eight studies are awaiting classification (see: <a href="./references#CD012024-sec-0207" title="">Characteristics of studies awaiting classification</a>) and four studies are ongoing. </p> </section> <section id="CD012024-sec-0088"> <h4 class="title">Included studies</h4> <section id="CD012024-sec-0089"> <h5 class="title">Design</h5> <p>All 16 randomised trials included in this review were placebo‐controlled and double‐blind, with the exception of one unblinded study (<a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>). All trials compared progesterone with placebo or no treatment; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a> conducted a three‐arm trial comparing two different doses of progesterone with placebo. </p> </section> <section id="CD012024-sec-0090"> <h5 class="title">Sample sizes</h5> <p>Sixteen included trials randomised 4548 women with a multiple pregnancy. Sample sizes from the individual trials ranged from n = 30 (<a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>) to n = 677 (<a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>), with a median of n = 225 participants. </p> </section> <section id="CD012024-sec-0091"> <h5 class="title">Setting</h5> <p>Trials took place in hospital clinics in the following countries: Austria, Brazil, Canada, Denmark, Egypt (one), Finland, France, Lebanon, Netherlands, Spain, Turkey, the UK and the USA (five). One trial took place in Austria and Denmark (<a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>). Several additional trials were conducted at multiple sites (<a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>). Women receiving intramuscular (IM) injections often had these administered weekly following presentation to an antenatal clinic. Women allocated to daily progesterone suppositories or gels often self‐administered this medication at home. </p> </section> <section id="CD012024-sec-0092"> <h5 class="title">Dates of trials, funding and conflicts of interest</h5> <p>Women were recruited to trials between 2004 to 2011, except for <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a> and <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>, where dates of recruitment were not clear. </p> <p>Four trials did not report whether or not trialists had any conflicts of interest (<a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>). All remaining trials reported that there were no conflicts of interest. </p> <p>Funding sources were not reported in four trials (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>). <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a> and <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a> reported that pharmaceutical companies had supplied the study drugs, and <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>, <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>, and <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a> appeared to be supported by grants from pharmaceutical companies. All remaining trials appeared to be funded by grants from university or government research funds. </p> </section> <section id="CD012024-sec-0093"> <h5 class="title">Participants</h5> <p>One trial recruited only women with a triplet pregnancy (<a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>). Women with a triplet pregnancy were also eligible for inclusion in <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>, <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a> and <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>. All remaining trials were of women with a twin pregnancy. Most studies involving women with a twin pregnancy specifically excluded monochorionic twins or women at risk of twin‐transfusion syndrome. However, <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a> included some women with a monochorionic twin pregnancy. Most trials excluded pregnant women with medical conditions, ruptured membranes, the presence of a cervical cerclage, or women who presented with symptoms or signs of labour. All trials excluded pregnant women where a fetal anomaly had been identified. </p> <p>Assessment of risk of preterm birth varied across trials. <a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a> recruited women who conceived following assisted reproduction (predominantly through IVF or ICSI). <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a> recruited pregnant women with a history of one previous spontaneous preterm birth. <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a> recruited women with an ultrasound‐identified short cervix (defined as &lt; 25 mm), between 24 and 31 weeks' gestation. In contrast, <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a> excluded women with a previous spontaneous preterm birth prior to 34 weeks' gestation, and <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a> recruited only women who conceived twins spontaneously, and with no history of preterm birth before 37 weeks. </p> <p>Gestational age at the time of trial entry varied across the included trials. <a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>, <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>, <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>, <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a> and <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a> all randomised women at between 16 and 20 weeks' gestation. <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a> randomised women between 16 and 22 weeks, while <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a> included women between 15 and 23 weeks' gestation. <a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>, <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>, <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a> and <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a> included pregnant women from between 18 or 20 weeks' and 24 weeks' gestation. The remaining trials randomised pregnant women at later gestational ages: <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a> between 20 and 30 weeks; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a> between 24 and 34 weeks; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a> between 24 and 31 weeks; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a> between 28 and 37 weeks; and <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a> between 24 and 34 weeks' gestation. </p> </section> <section id="CD012024-sec-0094"> <h5 class="title">Interventions and comparisons</h5> <section id="CD012024-sec-0095"> <h6 class="title">Vaginal progesterone</h6> <p>Seven trials (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>) evaluated vaginal progesterone suppositories, ovules or gel. Daily doses ranged from 90 mg per day (<a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>) up to 400 mg per day (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>). </p> </section> <section id="CD012024-sec-0096"> <h6 class="title">IM progesterone</h6> <p>Nine trials (<a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>) evaluated weekly IM injection of 17‐hydroxyprogesterone caproate. All used a single weekly dose of 250 mg, with the exception of <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>, which used twice‐weekly administration of 500 mg. </p> </section> </section> <section id="CD012024-sec-0097"> <h5 class="title">Outcomes</h5> <p>All included trials contributed data to the meta‐analyses of the prespecified outcomes in the review. </p> <p>Reporting of the primary outcome varied across the individual trials, although most identified preterm birth prior to 34 weeks (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>), 35 weeks (<a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>), or 37 weeks gestation (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>). Five trials used a composite primary outcome, including death or birth prior to 34 weeks' gestation (<a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>), death or birth prior to 35 weeks' gestation (<a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>), or a composite of neonatal adverse outcomes (<a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>) (<i>see</i><a href="#CD012024-tbl-0003">Table 1</a>). Gestational age at birth was the primary outcome for three additional trials (<a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>), and one trial reported the interval from randomisation to birth (<a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>). The primary outcome for the trial by <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a> was unclear. </p> <div class="table" id="CD012024-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reporting of fetal, neonatal and perinatal death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fetal death (FD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intrapartum death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stillbirth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal death (NND)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Perinatal death (PND)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included in </b><a href="./references#CD012024-bbs2-0113" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a><b>?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decision for PND for multiples review?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. "><b>Aboulghar 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as maternal outcome. From text appears as if at least one pregnancy affected by demise of both twins </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cannot reliably convert maternal denominator for neonatal outcome.</p> <p>Data not included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. "><b>Awwad 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a baby outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Include</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. "><b>Cetingoz 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No death data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No PND reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. "><b>Serra 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal death reported as maternal outcome and only as a single co‐twin demise outcome. Unsure if any pregnancies where both twins died </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a baby outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. Cannot convert fetal death into a baby outcome because only reported if single twin demise likely to underestimate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. "><b>Norman 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as a maternal outcome and denominator not clear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. "><b>Rode 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. as maternal outcome but specifies only 1 twin affected in each of those pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. "><b>Wood 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as infant outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. "><b>Awwad 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as infant outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. "><b>Briery 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No PND reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). "><b>Combs 2010</b> </a><b> triplets</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). "><b>Combs 2011</b> </a><b> twins</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. "><b>Hartikainen‐Sorri 1980</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. "><b>Lim 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or more died during delivery after 24 wks and also any IUD before onset labour or onset delivery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported “all live births”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No, and cannot be reliably added up from data presented</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. "><b>Rouse 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, from text (not in table)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ‐ not sure why data not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. "><b>Senat 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Can add NND and FD (IP and IU); all Ns clear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ‐ not sure why data not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes.</p> <p>Extrapolated from text and checked</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. "><b>Caritis 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a maternal outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cannot add FD and NND because FD reported as a maternal outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IP: intrapartum<br/> IU: intra‐uterine<br/> IUD: intra‐uterine death<br/> N/A: not applicable<br/> wk: week </p> </div> </div> </section> </section> <section id="CD012024-sec-0098"> <h4 class="title">Excluded studies</h4> <p>Most trials were excluded as they did not include women with a multiple pregnancy, or where the methodology adopted was clearly not randomised (e.g. secondary analysis or quasi‐randomisation). We also excluded trials if progesterone was intended as a tocolytic or used solely in the first trimester to prevent miscarriage. Please see the <a href="#CD012024-sec-0098">Excluded studies</a> table for further details. </p> </section> </section> <section id="CD012024-sec-0099"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD012024-sec-0100"> <h4 class="title">Allocation</h4> <p>An adequate process of random sequence generation was described for most included trials, although risk of bias was unclear in the trial conducted by <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>. We rated allocation concealment at low risk of bias for all trials; trialists described using sealed opaque envelopes (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>), a centralised allocation process (<a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>), or the use of identical‐appearing treatment packs (<a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>) to conceal allocation. </p> </section> <section id="CD012024-sec-0101"> <h4 class="title">Blinding</h4> <p>Most of the trials were placebo‐controlled and we assessed them at low risk of performance and outcome detection bias. Blinding of participants, caregivers and staff was not achieved in <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>, and was unclear for <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>. Blinding of outcome assessors was unclear in <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>, and <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>. </p> </section> <section id="CD012024-sec-0102"> <h4 class="title">Incomplete outcome data</h4> <p>There were 10% or less missing outcome data for most of the included trials (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>). Missing outcome data were more than 20% in <a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>. </p> </section> <section id="CD012024-sec-0103"> <h4 class="title">Selective reporting</h4> <p>We judged five trials (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>) to be at high risk of selective outcome reporting, as the study was either registered retrospectively (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>) or was not registered and did not have a published protocol (<a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>). We rated <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a> at unclear risk and the remaining trials at low risk of bias for this domain. </p> </section> <section id="CD012024-sec-0104"> <h4 class="title">Other potential sources of bias</h4> <p>There was no clear evidence of other potential sources of bias, although some trials provided limited information on methods. </p> <p>See <a href="#CD012024-fig-0002">Figure 2</a> for an overall summary of risk of bias assessments. </p> <div class="figure" id="CD012024-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> <section id="CD012024-sec-0105"> <h3 class="title" id="CD012024-sec-0105">Effects of interventions</h3> <p>See: <a href="./full#CD012024-tbl-0001"><b>Summary of findings for the main comparison</b> Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</a>; <a href="./full#CD012024-tbl-0002"><b>Summary of findings 2</b> Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</a> </p> <p>For a summary of main findings with an assessment of the quality of the evidence for key outcomes for the main comparisons (1) IM progesterone versus placebo or no treatment, and (2) vaginal progesterone versus placebo or no treatment, please <i>see</i><a href="./full#CD012024-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD012024-tbl-0002">summary of findings Table 2</a>. </p> <p>Outcomes are presented for the following comparisons.</p> <p> <ol id="CD012024-list-0018"> <li> <p>IM progesterone versus placebo (subgroup by weekly dose and subgroup by timing of start of therapy) </p> </li> <li> <p>Vaginal progesterone versus placebo (subgroup by weekly dose and subgroup by timing of start of therapy) </p> </li> <li> <p>IM progesterone versus no treatment (multiple pregnancy and short cervix)</p> </li> <li> <p>Vaginal progesterone versus placebo (multiple pregnancy and other risk factor)</p> </li> </ol> </p> <p>We report the results for each subgroup. Where there is evidence of subgroup differences, we report the results of the interaction tests and the effect estimates in subgroups. </p> <section id="CD012024-sec-0106"> <h4 class="title">Comparison 1: Intramuscular (IM) progesterone versus placebo</h4> </section> <section id="CD012024-sec-0107"> <h4 class="title">Subgroup by weekly dose (≤ 250 mg per week OR &gt; 250 mg per week)</h4> </section> <section id="CD012024-sec-0108"> <h4 class="title">Subgroup by timing of start of therapy (&lt; 20 weeks versus &gt; 20 weeks versus mixed gestational age) </h4> <section id="CD012024-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD012024-sec-0110"> <h6 class="title">1.1 Maternal mortality</h6> <p>There were no trials included in this review which reported maternal mortality.</p> </section> <section id="CD012024-sec-0111"> <h6 class="title">1.2 Preterm birth less than 34 weeks</h6> <p>IM progesterone was associated with an increase in risk of preterm birth prior to 34 weeks' gestation (risk ratio (RR) 1.54, 95% confidence interval (CI) 1.06 to 2.26; women = 399; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0003" title="">Analysis 1.1</a>, <i>low‐quality evidence</i>) when compared with placebo or no treatment, reflecting the increased risk of preterm birth observed in <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>, which used a higher weekly dose of 500 mg (RR 1.67, 95% CI 1.04 to 2.68; women = 161; studies = 1; <a href="./references#CD012024-fig-0004" title="">Analysis 1.2</a>). There were no clear group differences relating to the timing of the start of IM progesterone therapy for the risk of preterm birth before 34 weeks' gestation (test for subgroup differences: Chi<sup>2</sup> = 0.24, df = 1 (P = 0.62), I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD012024-sec-0112"> <h6 class="title">1.3 Perinatal death</h6> <p>There was no clear evidence that the use of IM progesterone was protective against perinatal death (average RR 1.45, 95% CI 0.60 to 3.51; infants = 3089; studies = 6; I<sup>2</sup> = 71%; <i>low‐quality evidence;</i><a href="./references#CD012024-fig-0006" title="">Analysis 1.4</a>) when compared with placebo or no treatment. Subgroup analysis by dose did not show a clear difference between high‐ and low‐dose subgroups; only one trial with a relatively small sample size used a higher weekly dose of progesterone (<a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>) <a href="./references#CD012024-fig-0007" title="">Analysis 1.5</a>) (test for subgroup differences: Chi<sup>2</sup> = 3.29, df = 1 (P = 0.07), I<sup>2</sup> = 69.6%). There were no apparent subgroup differences relating to the timing of the start of IM progesterone therapy and risk of perinatal death (test for subgroup differences: Chi<sup>2</sup> = 2.26, df = 2 (P = 0.32), I<sup>2</sup> = 11.6%; <a href="./references#CD012024-fig-0008" title="">Analysis 1.6</a>). (Sensitivity analysis assuming either complete dependence between multiples from the same pregnancy, or a low correlation between outcomes for multiples corresponded closely with the main analysis; <a href="./references#CD012024-fig-0029" title="">Analysis 1.27</a>; <a href="./references#CD012024-fig-0030" title="">Analysis 1.28</a>). </p> </section> <section id="CD012024-sec-0113"> <h6 class="title">1.4 Major neurodevelopmental disability at childhood follow‐up</h6> <p>There were no trials included in this review which reported childhood neurodevelopmental outcome. </p> </section> </section> <section id="CD012024-sec-0114"> <h5 class="title">Secondary outcomes ‐ Maternal</h5> <section id="CD012024-sec-0115"> <h6 class="title">Prelabour ruptured membranes</h6> <p>Women who received IM progesterone, placebo or no treatment had similar rates of prelabour ruptured membranes (RR 1.17, 95% CI 0.84 to 1.63; women = 1257; studies = 6; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD012024-sec-0116"> <h6 class="title">Preterm birth less than 37 weeks</h6> <p>Women who received IM progesterone, placebo or no treatment had similar rates of preterm birth before 37 weeks' gestation (RR 1.05, 95% CI 0.98 to 1.13; women = 2010; studies = 5; I<sup>2</sup> = 0%; <i>high‐quality evidence;</i><a href="./references#CD012024-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD012024-sec-0117"> <h6 class="title">Preterm birth less than 28 weeks</h6> <p>Women who received IM progesterone, placebo or no treatment had similar rates of risk of preterm birth before 28 weeks' gestation (RR 1.08, 95% CI 0.75 to 1.55; women = 1920; studies = 5; I<sup>2</sup> = 0%; <i>moderate‐quality evidence;</i><a href="./references#CD012024-fig-0011" title="">Analysis 1.9</a>). </p> </section> <section id="CD012024-sec-0118"> <h6 class="title">Adverse drug reaction</h6> <p>There were no clear group differences between women who received IM progesterone and those women who did not, in the experience of adverse effects relating to drug administration (average RR 0.91, 95% CI 0.63 to 1.32; women = 1316; studies = 2; I<sup>2</sup> = 81%; <a href="./references#CD012024-fig-0012" title="">Analysis 1.10</a>). </p> </section> <section id="CD012024-sec-0119"> <h6 class="title">Caesarean birth</h6> <p>Women who received IM progesterone, placebo or no treatment had similar rates of caesarean birth (RR 1.01, 95% CI 0.95 to 1.08; women = 2222; studies = 7; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0013" title="">Analysis 1.11</a>). </p> </section> <section id="CD012024-sec-0120"> <h6 class="title">Antenatal tocolysis</h6> <p>There were no clear differences between women who received IM progesterone and those women who did not, in their need for antenatal tocolysis (RR 0.97, 95% CI 0.85 to 1.10; women = 2218; studies = 7; I<sup>2</sup> = 19%; <a href="./references#CD012024-fig-0014" title="">Analysis 1.12</a>). </p> </section> <section id="CD012024-sec-0121"> <h6 class="title">Antenatal corticosteroids</h6> <p>There were no clear differences between women who received IM progesterone and those women who did not, in their need for antenatal corticosteroid administration (RR 0.99, 95% CI 0.88 to 1.11; women = 2221; studies = 7; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0015" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD012024-sec-0122"> <h5 class="title">Secondary outcomes ‐ Infant</h5> <section id="CD012024-sec-0123"> <h6 class="title">Infant birthweight less than 2500 g</h6> <p>Infants born to women who received IM progesterone and those who did not had similar rates of birthweight less than 2500 g (average RR 0.99, 95% CI 0.90 to 1.08; infants = 4071; studies = 5; I<sup>2</sup> = 76%; <i>moderate‐quality evidence</i>; <a href="./references#CD012024-fig-0016" title="">Analysis 1.14</a>). </p> </section> <section id="CD012024-sec-0124"> <h6 class="title">Apgar score less than seven at five minutes of age</h6> <p>Infants born to women who received IM progesterone and those who did not had similar rates of Apgar score less than seven at five minutes of age (RR 0.89, 95% CI 0.68 to 1.15; infants = 3606; studies = 4; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0017" title="">Analysis 1.15</a>). </p> </section> <section id="CD012024-sec-0125"> <h6 class="title">Neonatal sepsis</h6> <p>Infants born to women who received IM progesterone and those who did not had similar rates of neonatal sepsis (average RR 1.02, 95% CI 0.41 to 2.51; infants = 3327; studies = 6; I<sup>2</sup> = 79%; <a href="./references#CD012024-fig-0018" title="">Analysis 1.16</a>). </p> </section> <section id="CD012024-sec-0126"> <h6 class="title">Respiratory distress syndrome</h6> <p>Infants born to women who received IM progesterone and those who did not had similar rates of respiratory distress syndrome (average RR 1.07, 95% CI 0.85 to 1.34; participants = 4670; studies = 8; I² = 66%; <a href="./references#CD012024-fig-0019" title="">Analysis 1.17</a>). </p> </section> <section id="CD012024-sec-0127"> <h6 class="title">Use of mechanical ventilation</h6> <p>Infants born to women who received IM progesterone and those who did not had similar rates of mechanical ventilation (average RR 0.90, 95% CI 0.69 to 1.17; infants = 2233; studies = 3; I<sup>2</sup> = 43%; <a href="./references#CD012024-fig-0020" title="">Analysis 1.18</a>). </p> </section> <section id="CD012024-sec-0128"> <h6 class="title">Intraventricular haemorrhage</h6> <p>There were no group differences between infants born to women who received IM progesterone and those who did not, for the risk of intraventricular haemorrhage (RR 1.98, 95% CI 0.36 to 10.77; infants = 1355; studies = 1; <a href="./references#CD012024-fig-0021" title="">Analysis 1.19</a>), reported in a single study only. </p> </section> <section id="CD012024-sec-0129"> <h6 class="title">Retinopathy of prematurity</h6> <p>Infants born to women who received IM progesterone were at reduced risk of retinopathy of prematurity, although event rates were fairly low for this outcome (RR 0.34, 95% CI 0.16 to 0.74; infants = 2807; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0022" title="">Analysis 1.20</a>). </p> </section> <section id="CD012024-sec-0130"> <h6 class="title">Chronic lung disease</h6> <p>There were no clear group difference between infants born to women who received IM progesterone and those who did not for the risk of chronic lung disease (average RR 1.91, 95% CI 0.13 to 27.80; infants = 681; studies = 2; I<sup>2</sup> = 71%; <a href="./references#CD012024-fig-0023" title="">Analysis 1.21</a>). </p> </section> <section id="CD012024-sec-0131"> <h6 class="title">Necrotising enterocolitis</h6> <p>There was no clear difference in the rate of necrotising enterocolitis comparing infants born to women who received IM progesterone and those who did not (RR 0.74, 95% CI 0.36 to 1.51; infants = 2610; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0024" title="">Analysis 1.22</a>). </p> </section> <section id="CD012024-sec-0132"> <h6 class="title">Fetal death</h6> <p>There was no clear difference in the rate of fetal death comparing infants born to women who received IM progesterone and those who did not (average RR 0.93, 95% CI 0.39 to 2.20; infants = 3536; studies = 4; I<sup>2</sup> = 56%; <a href="./references#CD012024-fig-0025" title="">Analysis 1.23</a>). </p> </section> <section id="CD012024-sec-0133"> <h6 class="title">Neonatal death</h6> <p>There was no clear difference in the rate of neonatal death comparing infants born to women who received IM progesterone with those who did not (average RR 0.92, 95% CI 0.44 to 1.91; infants = 3399; studies = 7; I<sup>2</sup> = 35%; <a href="./references#CD012024-fig-0026" title="">Analysis 1.24</a>). </p> </section> <section id="CD012024-sec-0134"> <h6 class="title">Admission to neonatal intensive care unit</h6> <p>Infants born to women who received IM progesterone were more likely to require admission to the neonatal intensive care unit compared with infants born to women who did not (RR 1.33, 95% CI 1.13 to 1.58; infants = 1668; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0027" title="">Analysis 1.25</a>). </p> </section> <section id="CD012024-sec-0135"> <h6 class="title">Patent ductus arteriosus</h6> <p>Infants born to women who received IM progesterone and those who did not had a similar rate of patent ductus arteriosus (average RR 0.90, 95% CI 0.37 to 2.21; infants = 2290; studies = 4; I<sup>2</sup> = 74%; <a href="./references#CD012024-fig-0028" title="">Analysis 1.26</a>). </p> </section> </section> <section id="CD012024-sec-0136"> <h5 class="title">Secondary outcomes ‐ Child</h5> <p>None of the included studies evaluating IM progesterone reported childhood outcomes.</p> </section> </section> <section id="CD012024-sec-0137"> <h4 class="title">Comparison 2: Vaginal progesterone versus placebo</h4> </section> <section id="CD012024-sec-0138"> <h4 class="title">Subgroup by daily dose (≤ 200 mg per day versus &gt; 200 mg per day)</h4> </section> <section id="CD012024-sec-0139"> <h4 class="title">Subgroup by timing of start of therapy (&lt; 20 weeks versus &gt; 20 weeks versus mixed gestational age) </h4> <section id="CD012024-sec-0140"> <h5 class="title">Primary outcomes</h5> <section id="CD012024-sec-0141"> <h6 class="title">2.1 Maternal mortality</h6> <p>There were no trials included in this review reporting maternal mortality.</p> </section> <section id="CD012024-sec-0142"> <h6 class="title">2.2 Preterm birth less than 34 weeks</h6> <p>Women who received vaginal progesterone and those who did not had a similar risk of preterm birth before 34 weeks' gestation (average RR 0.90, 95% CI 0.66 to 1.23; women = 1503; studies = 5; I<sup>2</sup> = 36%; <i>low‐quality evidence</i>, <a href="./references#CD012024-fig-0031" title="">Analysis 2.1</a>). We carried out subgroup analysis by higher and lower weekly dose (<a href="./references#CD012024-fig-0032" title="">Analysis 2.2</a>) and by timing of progesterone (before and after 20 weeks' gestation and at a mixed gestational age (<a href="./references#CD012024-fig-0033" title="">Analysis 2.3</a>)). The subgroup interaction tests suggested no meaningful differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.36, df = 1 (P = 0.55), I<sup>2</sup> = 0%; test for subgroup differences: Chi<sup>2</sup> = 4.82, df = 2 (P = 0.09), I<sup>2</sup> = 58.5%). </p> </section> <section id="CD012024-sec-0143"> <h6 class="title">2.3 Perinatal death</h6> <p>There was no clear evidence to suggest that the use of vaginal progesterone was protective against perinatal death (RR 1.23, 95% CI 0.74 to 2.06; infants = 2287; studies = 3; I² = 0%; <i>low‐quality evidence;</i><a href="./references#CD012024-fig-0034" title="">Analysis 2.4</a>), with all studies reporting this outcome using a daily dose of vaginal progesterone of 200 mg or less. There was no evidence of a different effect relating to the timing of starting progesterone therapy (<a href="./references#CD012024-fig-0036" title="">Analysis 2.6</a>) (test for subgroup differences: Chi<sup>2</sup> = 0.23, df = 2 (P = 0.89), I<sup>2</sup> = 0%). Sensitivity analysis assuming either complete dependence between multiples from the same pregnancy, or a low correlation between outcomes for multiples corresponded closely with the main analysis; <a href="./references#CD012024-fig-0057" title="">Analysis 2.27</a>; <a href="./references#CD012024-fig-0058" title="">Analysis 2.28</a>). </p> </section> <section id="CD012024-sec-0144"> <h6 class="title">2.4 Major neurodevelopmental disability at childhood follow‐up</h6> <p>There were no trials included in this review reporting childhood neurodevelopmental outcomes. </p> </section> </section> <section id="CD012024-sec-0145"> <h5 class="title">Secondary outcomes ‐ Maternal</h5> <section id="CD012024-sec-0146"> <h6 class="title">Prelabour ruptured membranes</h6> <p>Women who received vaginal progesterone, placebo or no treatment had similar rates of prelabour ruptured membranes (RR 0.82, 95% CI 0.20 to 3.38; women = 290; studies = 1; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0037" title="">Analysis 2.7</a>). </p> </section> <section id="CD012024-sec-0147"> <h6 class="title">Preterm birth less than 37 weeks</h6> <p>Women who received vaginal progesterone, placebo or no treatment had similar rates of preterm birth before 37 weeks' gestation (RR 0.97, 95% CI 0.89 to 1.06; women = 1597; studies = 6; I<sup>2</sup> = 0%; <i>moderate‐quality evidence;</i><a href="./references#CD012024-fig-0038" title="">Analysis 2.8</a>). </p> </section> <section id="CD012024-sec-0148"> <h6 class="title">Preterm birth less than 28 weeks</h6> <p>Women who received vaginal progesterone, placebo or no treatment had similar rates of preterm birth before 28 weeks' gestation (RR 1.53, 95% CI 0.79 to 2.97 women = 1345; studies = 3; I<sup>2</sup> = 0%; <i>low‐quality evidence;</i><a href="./references#CD012024-fig-0039" title="">Analysis 2.9</a>). </p> </section> <section id="CD012024-sec-0149"> <h6 class="title">Adverse drug reaction</h6> <p>There were no group differences in the reporting of adverse effects relating to drug administration between women who received vaginal progesterone and those who did not (RR 0.99, 95% CI 0.90 to 1.09; women = 562; studies = 2; I<sup>2</sup> = 16%; <a href="./references#CD012024-fig-0040" title="">Analysis 2.10</a>). </p> </section> <section id="CD012024-sec-0150"> <h6 class="title">Caesarean birth</h6> <p>Women who received vaginal progesterone were less likely to give birth by caesarean section compared with women who did not (RR 0.92, 95% CI 0.86 to 0.98; women = 1919; studies = 5; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0041" title="">Analysis 2.11</a>). </p> </section> <section id="CD012024-sec-0151"> <h6 class="title">Maternal satisfaction with therapy</h6> <p>There was one study that reported a similar degree of satisfaction between women who received vaginal progesterone and those who did not (mean difference (MD) 0.00, 95% CI ‐0.35 to 0.35; women = 494; studies = 1; <a href="./references#CD012024-fig-0042" title="">Analysis 2.12</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>). </p> </section> <section id="CD012024-sec-0152"> <h6 class="title">Antenatal tocolysis</h6> <p>Women who received vaginal progesterone, placebo or no treatment had similar rates of antenatal tocolysis (RR 0.80, 95% CI 0.62 to 1.02; women = 1420; studies = 4; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0043" title="">Analysis 2.13</a>). </p> </section> <section id="CD012024-sec-0153"> <h6 class="title">Antenatal corticosteroids</h6> <p>Women who received vaginal progesterone, placebo or no treatment had similar rates of antenatal corticosteroid administration (RR 0.87, 95% CI 0.71 to 1.06; women = 1422; studies = 4; I<sup>2</sup> = 26%; <a href="./references#CD012024-fig-0044" title="">Analysis 2.14</a>). </p> </section> </section> <section id="CD012024-sec-0154"> <h5 class="title">Secondary outcomes ‐ Infant</h5> <section id="CD012024-sec-0155"> <h6 class="title">Infant birthweight less than 2500 g</h6> <p>Infants born to women who received vaginal progesterone compared to those who did not had similar rates of birthweight less than 2500 g (average RR 0.95, 95% CI 0.84 to 1.07; infants = 2640; studies = 3; I<sup>2</sup> = 66%; <i>moderate‐quality evidence;</i><a href="./references#CD012024-fig-0045" title="">Analysis 2.15</a>). </p> </section> <section id="CD012024-sec-0156"> <h6 class="title">Apgar score less than seven at five minutes of age</h6> <p>Infants born to women who received vaginal progesterone had similar rates of Apgar score less than seven at five minutes of age compared with those born to women who did not receive vaginal progesterone (RR 0.65, 95% CI 0.35 to 1.19; infants = 2410; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0046" title="">Analysis 2.16</a>). </p> </section> <section id="CD012024-sec-0157"> <h6 class="title">Respiratory distress syndrome</h6> <p>There were no clear differences between infants born to women who received vaginal progesterone and those who did not, for risk of respiratory distress syndrome (RR 0.98, 95% CI 0.78 to 1.22; infants = 2121; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0047" title="">Analysis 2.17</a>). </p> </section> <section id="CD012024-sec-0158"> <h6 class="title">Use of mechanical ventilation</h6> <p>Infants born to women who received vaginal progesterone were less likely to require mechanical ventilation than infants born to women who did not (RR 0.70, 95% CI 0.52 to 0.94; infants = 2695; studies = 4; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0048" title="">Analysis 2.18</a>). </p> </section> <section id="CD012024-sec-0159"> <h6 class="title">Intraventricular haemorrhage</h6> <p>Infants born to women who received vaginal progesterone compared to those who did not had similar rates of intraventricular haemorrhage (RR 1.70, 95% CI 0.62 to 4.66; infants = 1333; studies = 1; <a href="./references#CD012024-fig-0049" title="">Analysis 2.19</a>). </p> </section> <section id="CD012024-sec-0160"> <h6 class="title">Retinopathy of prematurity</h6> <p>Infants born to women who received vaginal progesterone compared to those who did not had similar rates of retinopathy of prematurity (RR 1.07, 95% CI 0.45 to 2.54; infants = 1945; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0050" title="">Analysis 2.20</a>). </p> </section> <section id="CD012024-sec-0161"> <h6 class="title">Necrotising enterocolitis</h6> <p>Infants born to women who received vaginal progesterone compared to those who did not had similar rates of necrotising enterocolitis (RR 0.52, 95% CI 0.13 to 2.06; infants = 2117; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0051" title="">Analysis 2.21</a>). </p> </section> <section id="CD012024-sec-0162"> <h6 class="title">Neonatal sepsis</h6> <p>There were no clear differences between infants born to women who received vaginal progesterone and those who did not, for risk of neonatal sepsis (RR 1.41, 95% CI 0.86 to 2.33; infants = 1944; studies = 2; I<sup>2</sup> = 19%; <a href="./references#CD012024-fig-0052" title="">Analysis 2.22</a>). </p> </section> <section id="CD012024-sec-0163"> <h6 class="title">Fetal death</h6> <p>There were no clear differences in the rate of fetal death between infants born to women who received vaginal progesterone and those who did not (RR 1.38, 95% CI 0.65 to 2.90; participants = 2328; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0053" title="">Analysis 2.23</a>). </p> </section> <section id="CD012024-sec-0164"> <h6 class="title">Neonatal death</h6> <p>There were no clear differences in the rate of neonatal death between infants born to women who received vaginal progesterone and those who did not (RR 1.53, 95% CI 0.75 to 3.15; infants = 2905; studies = 3; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0054" title="">Analysis 2.24</a>). </p> </section> <section id="CD012024-sec-0165"> <h6 class="title">Admission to neonatal intensive care unit (NICU)</h6> <p>There were no clear differences between infants born to women who received vaginal progesterone and those did not, for admission to the neonatal intensive care unit (average RR 0.95, 95% CI 0.83 to 1.08; infants = 3613; studies = 4; I<sup>2</sup> = 41%; <a href="./references#CD012024-fig-0055" title="">Analysis 2.25</a>). </p> </section> <section id="CD012024-sec-0166"> <h6 class="title">Patent ductus arteriosus</h6> <p>There were no clear differences between infants born to women who received vaginal progesterone for patent ductus arteriosus, compared with infants born to women who did not (RR 0.76, 95% CI 0.47 to 1.22; infants = 1946; studies = 2; I<sup>2</sup> = 0%; <a href="./references#CD012024-fig-0056" title="">Analysis 2.26</a>). </p> </section> </section> <section id="CD012024-sec-0167"> <h5 class="title">Secondary outcomes ‐ Child</h5> <p>None of the included studies evaluating vaginal progesterone reported childhood outcomes.</p> </section> </section> <section id="CD012024-sec-0168"> <h4 class="title">Further analysis by indication</h4> <p>All of the trials included in this review recruited and reported results for women with multiple pregnancy. However, in some trials there were additional clinical indications for the administration of progesterone, such as short cervix, or trials included only women from a particular population subgroup, such as women undergoing IVF. We therefore looked separately at trials where there were other indications, in comparisons 3 and 4; as in the main analysis, we examined IM and vaginal progesterone administration in separate comparisons. </p> <section id="CD012024-sec-0169"> <h5 class="title">Comparison 3: IM progesterone versus no treatment: multiple pregnancy and short cervix</h5> <p>A single trial (<a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>) contributed data to this comparison. In <a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a> 165 women with twin pregnancy and short cervix (25 mm or less) were recruited and treatment began at between 24 and 31<sup>+6</sup> weeks' gestation; 500 mg of IM 17‐alpha‐hydroxyprogesterone caproate was administered twice weekly until 36 weeks or preterm delivery, whichever occurred first (high dose). </p> <section id="CD012024-sec-0170"> <h6 class="title">Preterm birth less than 34 weeks</h6> <p>IM progesterone appeared to increase the risk of preterm birth before 34 weeks, although 95% CIs were wide (RR 1.67, 95% CI 1.04 to 2.68; women = 161; studies = 1; <a href="./references#CD012024-fig-0059" title="">Analysis 3.1</a>). </p> </section> <section id="CD012024-sec-0171"> <h6 class="title">Perinatal death</h6> <p>Perinatal death was also increased in the progesterone group in this trial with 9/164 and 1/166 deaths in the intervention and control groups respectively (RR 9.11, 95% CI 1.17 to 71.10; infants = 330; studies = 1; <a href="./references#CD012024-fig-0060" title="">Analysis 3.2</a>). </p> </section> <section id="CD012024-sec-0172"> <h6 class="title">Prelabour rupture of the membranes</h6> <p>There was no clear difference in the risk of prelabour rupture of the membranes between the women who received progesterone compared with women who received placebo (RR 1.14, 95% CI 0.63 to 2.06; women = 161; studies = 1; <a href="./references#CD012024-fig-0061" title="">Analysis 3.3</a>). </p> </section> <section id="CD012024-sec-0173"> <h6 class="title">Preterm birth less than 37 weeks</h6> <p>Women who received IM progesterone had similar rates of preterm birth before 37 weeks' gestation compared with women who received placebo (RR 1.06, 95% CI 0.90 to 1.25; women = 161; studies = 1; <a href="./references#CD012024-fig-0062" title="">Analysis 3.4</a>). </p> </section> <section id="CD012024-sec-0174"> <h6 class="title">Caesarean section</h6> <p>Women who received IM progesterone had similar rates of caesarean birth compared with women who received placebo (RR 1.14, 95% CI 0.88 to 1.49; women = 161; studies = 1; <a href="./references#CD012024-fig-0063" title="">Analysis 3.5</a>). </p> </section> <section id="CD012024-sec-0175"> <h6 class="title">Antenatal tocolysis</h6> <p>There was no clear difference in the numbers of women who required antenatal tocolysis between those who received IM progesterone compared with those who did not (RR 1.36, 95% CI 0.76 to 2.45; women = 158; studies = 1; <a href="./references#CD012024-fig-0064" title="">Analysis 3.6</a>). </p> </section> <section id="CD012024-sec-0176"> <h6 class="title">Antenatal corticosteroids</h6> <p>There was no clear difference in the numbers of women who required antenatal corticosteroids between those who received IM progesterone compared with those who did not (RR 0.93, 95% CI 0.64 to 1.36; women = 159; studies = 1; <a href="./references#CD012024-fig-0065" title="">Analysis 3.7</a>). </p> </section> <section id="CD012024-sec-0177"> <h6 class="title">Neonatal sepsis</h6> <p>Infants born to women who received progesterone had a similar incidence of sepsis to infants of women who did not receive progesterone (RR 5.03, 95% CI 0.60 to 42.57; infants = 303; studies = 1; <a href="./references#CD012024-fig-0066" title="">Analysis 3.8</a>). </p> </section> <section id="CD012024-sec-0178"> <h6 class="title">Respiratory distress syndrome</h6> <p>Infants born to women who received progesterone were slightly more likely to have respiratory distress syndrome compared with infants of women who did not receive progesterone (RR 1.46, 95% CI 1.00 to 2.12; infants = 309; studies = 1; <a href="./references#CD012024-fig-0067" title="">Analysis 3.9</a>). </p> </section> <section id="CD012024-sec-0179"> <h6 class="title">Retinopathy of prematurity</h6> <p>There was no clear difference in the number of infants with retinopathy of prematurity when comparing infants of women who received progesterone with infants of women who did not (RR 0.20, 95% CI 0.01 to 4.19); infants = 302; studies = 1; <a href="./references#CD012024-fig-0068" title="">Analysis 3.10</a>). </p> </section> <section id="CD012024-sec-0180"> <h6 class="title">Neonatal death</h6> <p>There was no clear difference in the risk of death in the neonatal period for infants of women who received progesterone compared with infants of women who did not (RR 4.03, 95% CI 0.46 to 35.61; infants = 307; studies = 1; <a href="./references#CD012024-fig-0069" title="">Analysis 3.11</a>). </p> </section> <section id="CD012024-sec-0181"> <h6 class="title">Admission to neonatal intensive care unit</h6> <p>There were more infants of women who received progesterone admitted to the neonatal intensive care unit compared with infants of women who did not receive progesterone (RR 1.34, 95% CI 1.04 to 1.74; infants = 313; studies = 1; <a href="./references#CD012024-fig-0070" title="">Analysis 3.12</a>). </p> <p>For perinatal death we carried out sensitivity analyses assuming total dependence and low dependence of outcomes for babies from the same pregnancy. If total dependence is assumed (i.e. all babies from the same pregnancy either survive or die) the evidence of a difference between groups for perinatal death was no longer statistically significant (RR 5.06, 95% CI 0.60 to 42.38; <a href="./references#CD012024-fig-0072" title="">Analysis 3.14</a>). </p> </section> </section> <section id="CD012024-sec-0182"> <h5 class="title">Comparison 4: Vaginal progesterone versus placebo: multiple pregnancy with another risk factor </h5> <p>Two studies are included in this comparison. <a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a> included 313 women at high risk of preterm birth, including 91 with twin pregnancy, with pregnancies conceived by IVF or ICSI. Women in the intervention group received vaginal progesterone 200 mg twice daily from randomisation until delivery or 37 weeks’ gestation, while controls received placebo. <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a> recruited women with twin pregnancies with other risk factors (previous history of preterm birth or uterine malformation or both (results not separated)). Women in the intervention group received micronised progesterone (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation; controls received placebo. </p> <p>Only two of our prespecified outcomes were reported in these studies: preterm birth at less than 34 and 37 weeks. There were no clear differences between groups in these studies, either individually or pooled, for either of these outcomes (preterm birth less than 34 weeks: RR 0.57, 95% CI 0.29 to 1.10; <a href="./references#CD012024-fig-0073" title="">Analysis 4.1</a>; preterm birth less than 37 weeks: RR 0.92, 95% CI 0.72 to 1.18; <a href="./references#CD012024-fig-0074" title="">Analysis 4.2</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012024-sec-0183" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012024-sec-0183"></div> <section id="CD012024-sec-0184"> <h3 class="title" id="CD012024-sec-0184">Summary of main results</h3> <p>Sixteen studies met our criteria for inclusion in the review; all of the identified trials contributed data to the analyses, with a combined sample size of 4548 women. Studies examined two main comparisons: intramuscular (IM) or vaginal progesterone versus placebo or no treatment. We also examined outcomes in women with additional risk factors for preterm birth, including short cervical length measured by ultrasound, and other risk factors. </p> <p>Overall across all comparisons, there were few clear differences between women receiving progesterone and women in the control groups, reflecting in part the small number of studies contributing data. </p> <p>In studies where women received IM progesterone compared with placebo, more women gave birth before the 34th week of pregnancy in the progesterone group than in the placebo group (<i>low‐quality evidence</i> ). There was no clear difference in the incidence of perinatal death between the groups (<i>low‐quality evidence</i> ). No studies reported whether any women died or whether the babies had longer‐term developmental problems or disability. There were no clear differences between women receiving progesterone or placebo for other important outcomes such as preterm birth less than 37 weeks (<i>high‐quality evidence</i> ); preterm birth less than 28 weeks (<i>moderate‐quality evidence</i> ) or infant birthweight less than 2500 g (<i>moderate‐quality evidence</i>). None of the prespecified childhood outcomes were reported in the trials. </p> <p>In studies where women received vaginal progesterone there were no clear differences between women receiving progesterone or placebo in preterm birth less than 34 weeks (<i>low‐quality evidence</i> ). Although there seemed to be fewer births before 34 weeks in the progesterone group, this finding may have occurred by chance. Incidence of perinatal death was similar in both groups (<i>low‐quality evidence</i> ). No studies reported maternal death or longer‐term outcomes in the babies. There were no clear differences between groups receiving vaginal progesterone versus placebo in any other important outcomes (preterm birth less than 37 weeks (<i>moderate‐quality evidence</i> ); preterm birth less than 28 weeks (<i>low‐quality evidence</i> ); infant birthweight less than 2500 g (<i>moderate‐quality evidence</i>)). None of the prespecified childhood outcomes were reported in the trials. For other outcomes, there were no clear group differences found except for caesarean section, where women who received vaginal progesterone did not have as many caesarean sections as those in the placebo group, although the difference between groups was not large (8%). Fewer infants whose mothers had received vaginal progesterone needed mechanical ventilation. </p> <p>In summary, for women with a multiple pregnancy, IM progesterone was associated with an increase in the risk of preterm birth prior to 34 weeks' gestation when compared to placebo or no treatment. For this comparison, where data were present (for secondary maternal and infant outcomes), there were no other differences identified. Vaginal progesterone was associated with similar risks of all relevant outcomes when compared with placebo or no treatment. </p> <p>For women with a multiple pregnancy and a short cervix, IM progesterone was associated with an apparent increase in the risk of preterm birth at less than 34 weeks, perinatal death and neonatal intensive care unit admission. However, these findings should be interpreted with considerable caution, based as they are on a single trial. </p> <p>Long‐term follow‐up was lacking in most of the included trials, and will be necessary to inform any impact on outcomes beyond the immediate neonatal period. </p> </section> <section id="CD012024-sec-0185"> <h3 class="title" id="CD012024-sec-0185">Overall completeness and applicability of evidence</h3> <p>The applicability of findings from this systematic review and meta‐analysis in women with a multiple pregnancy is broadly consistent with the findings reported in an individual participant data meta‐analysis (IPD‐MA) (<a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>). This individual participant review included data from 13 randomised trials, involving 3768 women and 7536 infants, where women were administered either IM or vaginal progesterone, or placebo. Overall, progesterone administration was not associated with any improvements in infant outcomes or reduction in the risk of preterm birth (<a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>). </p> <p>Outcomes for women with a triplet pregnancy remain under‐represented in this systematic review. Women with a triplet pregnancy were recruited exclusively in a single trial (<a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>). While three trials (<a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. ">Wood 2012</a>) included women with both a twin or a triplet pregnancy, outcome data were not reported separately according to plurality of the pregnancy, precluding further detailed assessment of the role of progesterone in this setting. </p> <p>An IPD‐MA has been performed in women with a triplet pregnancy, who received IM 17‐hydroxyprogesterone caproate or placebo (<a href="./references#CD012024-bbs2-0071" title="CombsCA , SchuitE , CaritisSN , LimAC , GariteTJ , MaurelK , et al. 17‐Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(5):682‐90. ">Combs 2016</a>). This IPD‐MA sourced data from three trials (<a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>), involving 232 women and 969 infants. Findings from this analysis did not indicate any beneficial effect of IM progesterone for risk of preterm birth prior to 34 (IM progesterone 86/136 (63%) versus placebo 64/96 (67%); risk ratio (RR) 0.95, 95% confidence interval (CI) 0.78 to 1.2) or 28 weeks' gestation (IM progesterone 15/136 (11%) versus placebo 12/96 (12%); RR 0.88, 95% CI 0.43 to 1.8), or in the occurrence of an adverse perinatal composite outcome comprising perinatal death, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, necrotising enterocolitis or neonatal sepsis (IM progesterone 140/408 (34%) versus placebo 101/288 (35%); RR 0.98, 95% CI 0.79 to 1.2) (<a href="./references#CD012024-bbs2-0071" title="CombsCA , SchuitE , CaritisSN , LimAC , GariteTJ , MaurelK , et al. 17‐Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(5):682‐90. ">Combs 2016</a>). </p> <p>It was difficult to assess any additional contribution to the risk of preterm birth for women with a multiple pregnancy, due to the presence of further clinical risk factors, reflecting variable reporting in the original trials. A single trial (<a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. ">Senat 2013</a>) specifically recruited women with a multiple pregnancy and a short cervical length identified by ultrasound assessment (less than 25 mm). While other trials included women with a cervical cerclage (<a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>), most trials specifically excluded women with evidence of cervical dilatation, or planned or current placement of a cervical suture (<a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. ">Awwad 2015</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. ">Caritis 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). ">Combs 2010</a>; <a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. ">Lim 2011</a>; <a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. ">Norman 2009</a>; <a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. ">Rouse 2007</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>). </p> <p>The IPD‐MA by <a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>, while identifying no apparent benefit following progesterone therapy overall, did identify a suggestion of benefit from the subgroup of women with a multiple pregnancy and cervical length below 25 mm on ultrasound examination at the time of randomisation following vaginal progesterone administration, with a reduction in the risk of adverse perinatal outcome (vaginal progesterone 15/56 versus placebo 22/60; RR 0.57, 95% CI 0.47 to 0.70) (<a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>). In a subsequent updated IPD‐MA involving data from five randomised trials (<a href="./references#CD012024-bbs2-0004" title="AgraIK , BrizotML , MiyadahiraMY , CarvalhoMH , FranciscoRP , ZugaibM . The effect of prenatally administered vaginal progesterone on uterine artery doppler in asymptomatic twin pregnancies. European Journal of Obstetrics &amp; Gynecology, and Reproductive Biology2016; Vol. 205:11‐4. BrizotML , HernandezW , LiaoAW , BittarRE , FranciscoRP , KrebsVL , et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo‐controlled double‐blind study. American Journal of Obstetrics and Gynecology2015;213:82.e1‐9. DeOliveiraLA , BrizotML , LiaoAW , BittarRE , FranciscoRP , ZugaibM . Prenatal administration of vaginal progesterone and frequency of uterine contractions in asymptomatic twin pregnancies. Acta Obstetricia et Gynecologica Scandinavica2016;95(4):436‐43. ">Brizot 2015</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0051" title="El‐RefaieW , AbdelhafezMS , BadawyA . Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Archives of Gynecology and Obstetrics2016;293(1):61‐7. ">El‐Refaie 2016</a>; <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a>; <a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. ">Serra 2013</a>) specifically recruiting women with a multiple pregnancy, and additional data from a trial involving a small number of women with a multiple pregnancy and short cervix (<a href="./references#CD012024-bbs2-0053" title="FonsecaEB , CelikE , ParraM , SinghM , NicolaidesKH , for the Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine2007;357(5):462‐9. ">Fonseca 2007</a>), data were available from 303 women with a multiple pregnancy and their 606 infants (<a href="./references#CD012024-bbs2-0099" title="RomeroR , Conde‐AgudeloA , El‐RefaieW , RodeL , BrizotML , CetingozE , et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta‐analysis of individual patient data. Ultrasound in Obstetrics &amp; Gynecology2017;49(3):303‐14. ">Romero 2017</a>). Women who received vaginal progesterone therapy with a short cervical length appeared less likely to give birth before 34 weeks' gestation (vaginal progesterone 63/159 versus placebo 78/144; RR 0.71, 95% CI 0.56 to 0.91), with a reduction in risk of a composite adverse perinatal outcome (vaginal progesterone 23/84 versus placebo 28/70; RR 0.61, 95% CI 0.34 to 0.98), accounting for non‐independence of outcomes between infants of a multiple pregnancy (<a href="./references#CD012024-bbs2-0099" title="RomeroR , Conde‐AgudeloA , El‐RefaieW , RodeL , BrizotML , CetingozE , et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta‐analysis of individual patient data. Ultrasound in Obstetrics &amp; Gynecology2017;49(3):303‐14. ">Romero 2017</a>). Some of the significant findings reported in this IPD‐MA (namely, preterm birth prior to 33 weeks' gestation, and neonatal death) became statistically non‐significant when accounting for trial quality and blinding of participants, staff and outcome assessors (<a href="./references#CD012024-bbs2-0099" title="RomeroR , Conde‐AgudeloA , El‐RefaieW , RodeL , BrizotML , CetingozE , et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta‐analysis of individual patient data. Ultrasound in Obstetrics &amp; Gynecology2017;49(3):303‐14. ">Romero 2017</a>). </p> <p>While IPD‐MA can be used to identify particular subgroups for whom an intervention may be effective (<a href="./references#CD012024-bbs2-0107" title="StewartLA , TierneyJF , Clarke , M , Cochrane Individual Patient Data Meta‐analysis Methods Group. Chapter 18: Reviews of individual patient data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Stewart 2011</a>), interpretation of findings should consider the overall impact of the intervention, recognising the implications of the relatively small sample size and issues relating to adequate statistical power (<a href="./references#CD012024-bbs2-0108" title="SunX , IoannidisJP , AgoritsasT , AlbaAC , GuyattG . How to use a subgroup analysis: users' guide to the medical literature. JAMA2014;311(4):405‐11. ">Sun 2014</a>; <a href="./references#CD012024-bbs2-0112" title="YusufS , WittesJ , ProbstfieldJ , TyrolerHA . Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA1991;266(1):93‐8. ">Yusuf 1991</a>). The two IPD reviews have included a relatively small subgroup of women with a multiple pregnancy who received progesterone therapy, and while there is a suggestion of benefit, results should be interpreted with caution. Although preterm birth is recognised to be a heterogeneous condition (<a href="./references#CD012024-bbs2-0098" title="RomeroR , EspinozaJ , KusanovicJP , GotschF , HassanS , ErezO , et al. The preterm parturition syndrome. BJOG: an international journal of obstetrics and gynaecology2006;113(Suppl 3):17‐42. ">Romero 2006</a>), consideration should also be given to the possible biological mechanism whereby benefit is only observed in a very specific subgroup of women. </p> <p>The longer‐term effects of exposure to progesterone during pregnancy have so far been reported in a limited number of studies (<a href="./references#CD012024-bbs2-0090" title="McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT Baby Follow‐up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PloS One2015;10(4):e0122341. ">McNamara 2015</a>; <a href="./references#CD012024-bbs2-0111" title="VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Vedel 2016</a>), although the available evidence does not suggest an increased risk of harms extending into childhood. In the follow‐up of the STOPPIT trial (<a href="./references#CD012024-bbs2-0090" title="McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT Baby Follow‐up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PloS One2015;10(4):e0122341. ">McNamara 2015</a>), record linkage studies were performed to assess outcomes at three to six years of age, with data available for 97% of participants. Using these data, there were no differences in risk of death, hospitalisation, congenital anomalies, or outcomes at routine childhood health assessments (<a href="./references#CD012024-bbs2-0090" title="McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT Baby Follow‐up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PloS One2015;10(4):e0122341. ">McNamara 2015</a>). Follow‐up of the <a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Rode 2011</a> trial (<a href="./references#CD012024-bbs2-0111" title="VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Vedel 2016</a>) performed neurophysiological assessment at 48 or 60 months of age. There were no apparent differences in the number of hospital admissions or risk of low score using the Ages and Stages Questionnaire to screen for neurodevelopment (<a href="./references#CD012024-bbs2-0111" title="VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. ">Vedel 2016</a>). Further data relating to childhood follow‐up from other randomised trials would be beneficial. </p> </section> <section id="CD012024-sec-0186"> <h3 class="title" id="CD012024-sec-0186">Quality of the evidence</h3> <p>Overall, we rated the included studies at low risk of bias, although five studies were assessed at high risk of bias for selective outcome reporting (<a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. ">Aboulghar 2012</a>; <a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. ">Briery 2009</a>; <a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. ">Cetingoz 2011</a>; <a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). ">Combs 2011</a>; <a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. ">Hartikainen‐Sorri 1980</a>). We judged sequence generation to be adequate in most of the included studies, and appropriate blinding was also achieved. Most included studies had less than 10% sample attrition. </p> <p>We used GRADE to assess the outcomes of perinatal mortality, preterm birth less than 34 weeks, major neurodevelopmental disability at childhood follow‐up, infant birthweight less than 2500 g, birth before 37 completed weeks and birth before 28 completed weeks. The 'Summary of findings' tables show the quality of evidence across these critical outcomes to be low to high. The main reason for downgrading the quality of the evidence was due to imprecision in the effect estimates, inconsistency and for some outcomes design limitations in some of the studies contributing data. </p> </section> <section id="CD012024-sec-0187"> <h3 class="title" id="CD012024-sec-0187">Potential biases in the review process</h3> <p>The inclusion criteria for this review were reasonably broad, in order to evaluate the available evidence, which always includes trials with a range of inclusion criteria. The individual trial characteristics highlight the variation in inclusion criteria, the timing of starting progesterone therapy, the route of progesterone administration and the dose of progesterone given. The available information for specific subgroups of women with a multiple pregnancy are inevitably limited by the characteristics of the included studies. </p> <p>We acknowledge that there is the potential for bias at all stages of performing a systematic review. We attempted to minimise bias in a number of ways; for example, two review authors independently carried out data extraction and assessed risk of bias. </p> </section> <section id="CD012024-sec-0188"> <h3 class="title" id="CD012024-sec-0188">Agreements and disagreements with other studies or reviews</h3> <p>As highlighted above, the findings of our review are broadly consistent with the IPD‐MA reported by <a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>, derived from a smaller number of included trials and participants, but concluding that the overall administration of progesterone to women with a multiple pregnancy was not associated with any improvements in infant outcomes or reduction in risk of preterm birth. Furthermore, the evidence presented by <a href="./references#CD012024-bbs2-0071" title="CombsCA , SchuitE , CaritisSN , LimAC , GariteTJ , MaurelK , et al. 17‐Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2016;123(5):682‐90. ">Combs 2016</a> does not suggest that there is a benefit associated with IM progesterone, specifically in women with a triplet pregnancy. The effect of vaginal progesterone in women with a triplet pregnancy has so far been under evaluated. While there is a suggestion that vaginal progesterone may be associated with a reduction in risk of preterm birth and improved neonatal outcomes in women with a multiple pregnancy and short cervical length (<a href="./references#CD012024-bbs2-0099" title="RomeroR , Conde‐AgudeloA , El‐RefaieW , RodeL , BrizotML , CetingozE , et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta‐analysis of individual patient data. Ultrasound in Obstetrics &amp; Gynecology2017;49(3):303‐14. ">Romero 2017</a>; <a href="./references#CD012024-bbs2-0102" title="SchuitE , StockS , RodeL , RouseDJ , LimAC , NormanJE , et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta‐analysis. BJOG: an international journal of obstetrics and gynaecology2015;122(1):27‐37. ">Schuit 2014</a>), these IPD‐MAs reflect subgroups of women only, and have involved relatively small numbers of participants. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012024-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 1 Preterm birth less than 34 weeks." data-id="CD012024-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 1 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 2 Preterm birth less than 34 weeks subgroup by dose." data-id="CD012024-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 2 Preterm birth less than 34 weeks subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 3 Preterm birth less than 34 week subgroup by timing." data-id="CD012024-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 3 Preterm birth less than 34 week subgroup by timing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 4 Perinatal death." data-id="CD012024-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 4 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 5 Perinatal death subgroup by dose." data-id="CD012024-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 5 Perinatal death subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 6 Perinatal death subgroup by timing." data-id="CD012024-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 6 Perinatal death subgroup by timing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 7 Prelabour rupture of the membranes." data-id="CD012024-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 7 Prelabour rupture of the membranes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 8 Preterm birth less than 37 weeks." data-id="CD012024-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 8 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 9 Preterm birth less than 28 weeks." data-id="CD012024-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 9 Preterm birth less than 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 10 Adverse drug reaction." data-id="CD012024-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 10 Adverse drug reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 11 Caesarean section." data-id="CD012024-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 11 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 12 Antenatal tocolysis." data-id="CD012024-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 12 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 13 Antenatal corticosteroids." data-id="CD012024-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 13 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 14 Infant birthweight less than 2500 g." data-id="CD012024-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 14 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 15 Apgar score &lt; 7 at 5 minutes." data-id="CD012024-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 15 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 16 Neonatal sepsis." data-id="CD012024-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 16 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 17 Respiratory distress syndrome." data-id="CD012024-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 17 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 18 Use of mechanical ventilation." data-id="CD012024-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 18 Use of mechanical ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 19 Intraventricular haemorrhage ‐ all grades." data-id="CD012024-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 19 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 20 Retinopathy of prematurity." data-id="CD012024-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 20 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 21 Chronic lung disease." data-id="CD012024-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 21 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 22 Necrotising enterocolitis." data-id="CD012024-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 22 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 23 Fetal death." data-id="CD012024-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 23 Fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 24 Neonatal death." data-id="CD012024-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 24 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 25 Admission to NICU." data-id="CD012024-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 25 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 26 Patent ductus arteriosus." data-id="CD012024-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 26 Patent ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 27 Sensitivity analysis for perinatal death (assuming total dependence)." data-id="CD012024-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 27 Sensitivity analysis for perinatal death (assuming total dependence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 28 Sensitivity analysis for perinatal death (assuming 1% dependence)." data-id="CD012024-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Intramuscular (IM) progesterone versus no treatment or placebo, Outcome 28 Sensitivity analysis for perinatal death (assuming 1% dependence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 1 Preterm birth less than 34 weeks." data-id="CD012024-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 1 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 2 Preterm birth less than 34 weeks subgroup by dose." data-id="CD012024-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 2 Preterm birth less than 34 weeks subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 3 Preterm birth less than 34 weeks subgroup by timing." data-id="CD012024-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 3 Preterm birth less than 34 weeks subgroup by timing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 4 Perinatal death." data-id="CD012024-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 4 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 5 Perinatal death subgroup by dose." data-id="CD012024-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 5 Perinatal death subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 6 Perinatal death subgroup by timing." data-id="CD012024-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 6 Perinatal death subgroup by timing. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 7 Prelabour rupture of the membranes." data-id="CD012024-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 7 Prelabour rupture of the membranes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 8 Preterm birth less than 37 weeks." data-id="CD012024-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 8 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 9 Preterm birth less than 28 weeks." data-id="CD012024-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 9 Preterm birth less than 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 10 Adverse drug reaction." data-id="CD012024-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 10 Adverse drug reaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 11 Caesarean section." data-id="CD012024-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 11 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 12 Satisfaction with therapy." data-id="CD012024-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 12 Satisfaction with therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 13 Antenatal tocolysis." data-id="CD012024-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 13 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 14 Antenatal corticosteroids." data-id="CD012024-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 14 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 15 Infant birthweight less than 2500 g." data-id="CD012024-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 15 Infant birthweight less than 2500 g. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 16 Apgar score &lt; 7 at 5 minutes." data-id="CD012024-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 16 Apgar score &lt; 7 at 5 minutes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 17 Respiratory distress syndrome." data-id="CD012024-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 17 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 18 Use of mechanical ventilation." data-id="CD012024-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 18 Use of mechanical ventilation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 19 Intraventricular haemorrhage ‐ all grades." data-id="CD012024-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 19 Intraventricular haemorrhage ‐ all grades. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 20 Retinopathy of prematurity." data-id="CD012024-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 20 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 21 Necrotising enterocolitis." data-id="CD012024-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 21 Necrotising enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 22 Neonatal sepsis." data-id="CD012024-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 22 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 23 Fetal death." data-id="CD012024-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 23 Fetal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 24 Neonatal death." data-id="CD012024-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 24 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 25 Admission to NICU." data-id="CD012024-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 25 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 26 Patent ductus arteriosus." data-id="CD012024-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 26 Patent ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 27 Sensitivity analysis for perinatal death (assuming total non‐independence)." data-id="CD012024-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 27 Sensitivity analysis for perinatal death (assuming total non‐independence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 28 Sensitivity analysis for perinatal death (assuming 1% non‐independence)." data-id="CD012024-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Vaginal progesterone versus no treatment or placebo, Outcome 28 Sensitivity analysis for perinatal death (assuming 1% non‐independence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 1 Preterm birth less than 34 weeks." data-id="CD012024-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 1 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 2 Perinatal death." data-id="CD012024-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 2 Perinatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 3 Prelabour rupture of the membranes." data-id="CD012024-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 3 Prelabour rupture of the membranes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 4 Preterm birth less than 37 weeks." data-id="CD012024-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 4 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 5 Caesarean section." data-id="CD012024-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 5 Caesarean section. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 6 Antenatal tocolysis." data-id="CD012024-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 6 Antenatal tocolysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 7 Antenatal corticosteroids." data-id="CD012024-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 7 Antenatal corticosteroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 8 Neonatal sepsis." data-id="CD012024-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 8 Neonatal sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 9 Respiratory distress syndrome." data-id="CD012024-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 9 Respiratory distress syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 10 Retinopathy of prematurity." data-id="CD012024-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 10 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 11 Neonatal death." data-id="CD012024-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 11 Neonatal death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 12 Admission to NICU." data-id="CD012024-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 12 Admission to NICU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 13 Sensitivity analysis for perinatal death (assuming total dependence)." data-id="CD012024-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 13 Sensitivity analysis for perinatal death (assuming total dependence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 14 Sensitivity analysis for perinatal death (assuming 1% dependence)." data-id="CD012024-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix, Outcome 14 Sensitivity analysis for perinatal death (assuming 1% dependence). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Vaginal progesterone versus placebo: multiple pregnancy and another risk factor, Outcome 1 Preterm birth less than 34 weeks." data-id="CD012024-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Vaginal progesterone versus placebo: multiple pregnancy and another risk factor, Outcome 1 Preterm birth less than 34 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012024-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/urn:x-wiley:14651858:media:CD012024:CD012024-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_t/tCD012024-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Vaginal progesterone versus placebo: multiple pregnancy and another risk factor, Outcome 2 Preterm birth less than 37 weeks." data-id="CD012024-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Vaginal progesterone versus placebo: multiple pregnancy and another risk factor, Outcome 2 Preterm birth less than 37 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/media/CDSR/CD012024/image_n/nCD012024-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012024-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: W</b> omen with a multiple pregnancy<br/> <b>Setting:</b> Obstetric clinics in Finland, France, Lebanon, the Netherlands, and the USA<br/> <b>Intervention:</b> Intramuscular (IM) progesterone<br/> <b>Comparison:</b> No treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intramuscular (IM) progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.45<br/> (0.60 to 3.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3089<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (20 to 120) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 34 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.54<br/> (1.06 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>191 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>298 per 1000<br/> (204 to 436) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability at childhood follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trial reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infant birthweight less than 2500 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/> (0.90 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4071<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>613 per 1000<br/> (558 to 669) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 28 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/> (0.75 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1920<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (43 to 89) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 37 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.98 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2010<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>614 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1000<br/> (602 to 688) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Statistical heterogeneity (I<sup>2</sup> &gt; 60%). Variation in size and direction of effect (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect. (‐1).<br/> <sup>3</sup>Study with design limitations (lack of blinding) contributing data (64.2% weight) (‐1).<br/> <sup>4</sup>Wide confidence interval (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intramuscular (IM) progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012024-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Women with a multiple pregnancy<br/> <b>Setting:</b> Obstetric clinics in Austria, Brazil, Canada, Denmark, Egypt, Spain, Turkey and UK<br/> <b>Intervention:</b> Vaginal progesterone<br/> <b>Comparison:</b> No treatment or placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment or placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vaginal progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Perinatal death</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.23<br/> (0.74 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2287<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (17 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 34 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.66 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1503<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>162 per 1000<br/> (119 to 222) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major neurodevelopmental disability at childhood follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(0 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trial reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Infant birthweight less than 2500 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/> (0.84 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2640<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>542 per 1000<br/> (480 to 611) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 37 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.97<br/> (0.89 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1597<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>559 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>547 per 1000<br/> (503 to 598) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Preterm birth less than 28 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.53<br/> (0.79 to 2.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1345<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (18 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>One study contributing data with design limitations (weight of 52.1%) (‐1).<br/> <sup>2</sup>Wide confidence interval crossing the line of no effect (‐1).<br/> <sup>3</sup>Two studies contributing data with design limitations (combined weight 47.9%) (‐1).<br/> <sup>4</sup> Downgraded due to concerns relating to inconsistency ‐ evidence of statistical heterogeneity with an I‐squared value of 66% (‐1).<br/> <sup>5</sup>One study contributing data with design limitations (weight of 33.9%) (‐1).<br/> <sup>6</sup>Most of the pooled effect was provided by studies with design limitations (‐1). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vaginal progesterone compared to no treatment or placebo for preventing spontaneous preterm birth in women with a multiple pregnancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012024-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reporting of fetal, neonatal and perinatal death</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fetal death (FD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intrapartum death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stillbirth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neonatal death (NND)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Perinatal death (PND)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Included in </b><a href="./references#CD012024-bbs2-0113" title="DoddJM , JonesL , FlenadyV , CincottaR , CrowtherCA . Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD004947.pub3] ">Dodd 2013</a><b>?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Decision for PND for multiples review?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0001" title="AboulgharM , AboulgharM , AminY , Al InanyH , SerourG , MansourR . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(Suppl 1):19. AboulgharMM , AboulgharMA , AminYM , Al‐InanyHG , MansourRT , SerourGI . The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reproductive BioMedicine Online2012;25(2):133‐8. "><b>Aboulghar 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as maternal outcome. From text appears as if at least one pregnancy affected by demise of both twins </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cannot reliably convert maternal denominator for neonatal outcome.</p> <p>Data not included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. "><b>Awwad 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a baby outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Include</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0006" title="CetingozE , CamC , SakalliM , KaratekeA , CelikC , SancakA . Progesterone effects on preterm birth in high‐risk pregnancies: a randomized placebo‐controlled trial. Archives of Gynecology and Obstetrics2011;283(3):423‐9. "><b>Cetingoz 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No death data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No PND reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0015" title="NCT00480402 . Natural progesterone and preterm birth in twins. clinicaltrials.gov/ct2/show/NCT00480402 (first received 28 May 2007). SerraV , PeralesA , MeseguerJ , ParrillaJ , LaraC , BellverJ , et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double‐blind multicentre trial. BJOG: an international journal of obstetrics and gynaecology2013;120(1):50‐7. "><b>Serra 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal death reported as maternal outcome and only as a single co‐twin demise outcome. Unsure if any pregnancies where both twins died </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a baby outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported. Cannot convert fetal death into a baby outcome because only reported if single twin demise likely to underestimate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0011" title="EddamaO , PetrouS , RegierD , NorrieJ , MacLennanG , MacKenzieF , et al. Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial‐based cost‐effectiveness analysis. International Journal of Technology Assessment in Health Care2010;26(2):141‐8. ISRCTN35782581 . Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT) (ongoing trial). www.isrctn.com/ISRCTN35782581 (first received 10 June 2005). McNamaraHC , WoodR , ChalmersJ , MarlowN , NorrieJ , MacLennanG , et al. STOPPIT baby follow‐up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. Plos One2015;10(4):e0122341. NormanJE , MacKenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. A randomized, double‐masked, placebo‐controlled study of progesterone for the prevention of preterm birth of twins (STOPPIT). Archives of Disease in Childhood. Fetal and Neonatal Edition2009;94(Suppl 1):Fa8. NormanJE , MackenzieF , OwenP , MactierH , HanrettyK , CooperS , et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double‐blind, placebo‐controlled study and meta‐analysis. Lancet2009;373(9680):2034‐40. NormanJE , YuanM , AndersonL , HowieF , HaroldG , YoungA , et al. Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences2011;18(5):435‐46. "><b>Norman 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported as a maternal outcome and denominator not clear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0012" title="KleinK , RodeL , NicolaidesK , Krampl‐BettelheimE , LarsenH , HolmskovA , et al. Vaginal progesterone and the risk of preterm delivery in high‐risk twin gestations ‐ secondary analysis of a placebo‐controlled randomized trial. Ultrasound in Obstetrics &amp; Gynecology2011;38(S1):11. KleinK , RodeL , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high‐risk twin pregnancies: secondary analysis of a placebo‐controlled randomized trial and meta‐analysis. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):281‐7. RodeL , KleinK , LarsenH , HolmskovA , AndreasenKR , UldbjergN , et al. Cytokines and the risk of preterm delivery in twin pregnancies. Obstetrics and Gynecology2012;120(1):60‐8. RodeL , KleinK , NicolaidesK , Krampl‐BettelheimE , VogelI , LarsenH , et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicentre randomised placebo‐controlled trial on the effect of vaginal micronised progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(Suppl 1):1. RodeL , KleinK , NicolaidesKH , Krampl‐BettelheimE , TaborA , PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo‐controlled trial on the effect of vaginal micronized progesterone. Ultrasound in Obstetrics &amp; Gynecology2011;38(3):272‐80. VedelC , LarsenH , HolmskovA , AndreasenKR , UldbjergN , RambJ , et al. Long‐term effects of prenatal progesterone exposure: Neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound in Obstetrics &amp; Gynecology2016;48(3):382‐9. "><b>Rode 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes. as maternal outcome but specifies only 1 twin affected in each of those pregnancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0016" title="NCT00343265 . Vaginal progesterone versus placebo in multiple pregnancy. clinicaltrials.gov/ct2/show/NCT00343265 (first received 20 June 2006). SwabyC . Pilot randomized controlled trial of vaginal progesterone to prevent preterm birth in multiple pregnancy. JOGC: Journal of Obstetrics and Gynaecology Canada2007;29(6 Suppl 1):S47. WoodS , RossS , TangS , MillerL , SauveR , BrantR . Vaginal progesterone to prevent preterm birth in multiple pregnancy: A randomized controlled trial. Journal of Perinatal Medicine2012;40(6):593‐9. "><b>Wood 2012</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as infant outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0002" title="AwwadJ , UstaIM , GhazeeriG , YacoubN , SuccarJ , HayekS , et al. A randomised controlled double‐blind clinical trial of 17‐hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG: an international journal of obstetrics and gynaecology2015;122:71‐9. NCT00141908 . Prevention of preterm delivery in twin pregnancies by 17 alpha hydroxyprogesterone caproate. clinicaltrials.gov/ct2/show/NCT00141908 (first received 1 September 2005). NassarA , AwwadJ , SuccarJ , SaassouhW , KhalifeT , HayekS , et al. Incidence of GDM in twin pregnancies of women receiving prophylactic 17‐A OH progesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(S1):307‐8. "><b>Awwad 2015</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as infant outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0003" title="BrieryC , VeillonE , KlauserCK , MartinR , ChauhanS , MagannEF , et al. Women with prolonged premature rupture of the membrane do not benefit from weekly progesterone: a randomized clinical trial. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S189. BrieryCM , VeillonEW , KlauserCK , MartinRW , ChauhanSP , MagannEF , et al. Progesterone does not prevent preterm births in women with twins. Southern Medical Journal2009;102(9):900‐4. "><b>Briery 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No PND reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0007" title="CombsCA , GariteT , MaurelK , DasA , PortoM , for theOCRN . Failure of 17‐hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2010;203(3):248.e1‐248.e9. CombsCA , GariteT , PortoM , MaurelK , for theOCRN . 17‐hydroxyprogesterone for triplet pregnancy does not reduce prematurity or neonatal morbidity, may increase midtrimester loss. American Journal of Obstetrics and Gynecology2009;201(6 Suppl 1):S168. NCT00163020 . 17OHP for reduction of neonatal morbidity due to preterm birth (PTB) in twin and triplet pregnancies. clinicaltrials.gov/ct2/show/NCT00163020 (first received 9 September 2005). "><b>Combs 2010</b> </a><b> triplets</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0008" title="CombsCA , GariteJ , MaurelK , DasA . Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17‐hydroxyprogesterone caproate. American Journal of Perinatology2014;31(12):1023‐30. CombsCA , GariteT , MaurelK , DasA . Fetal fibronectin and cervical length as predictors of preterm birth in twin pregnancies, with or without 17‐hydroxyprogesterone caproate. American Journal of Obstetrics and Gynecology2013;208(1 Suppl 1):S205. CombsCA , GariteT , MaurelK , DasA , PortoM , for the Obstetrix Collaborative Research Network. 17‐hydroxyprogesterone caproate for twin pregnancy: a double‐blind, randomized clinical trial. American Journal of Obstetrics and Gynecology2011;204:221.e1‐221.e8. CombsCA , GariteTJ , MaurelK , CebrikD . 17‐hydroxyprogesterone caproate for women with history of preterm birth in a prior pregnancy and twins in the current pregnancy. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S213. CombsCA , MaurelK , GariteT , for the Obstetric Collaborative Research Network. 17‐hydroxyprogesterone for twin pregnancy: no reduction in prematurity or neonatal morbidity. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S7. HeitmannE , LuG , CombsCA , GariteTJ , MaurelK . The impact of maternal weight upon the effectiveness of 17‐hydroxyprogesterone in preventing preterm birth among twin gestations. American Journal of Obstetrics and Gynecology2012;206(Suppl 1):S98. HortonA , GyamfiC . 17‐alpha hydroxyprogesterone caproate does not increase the risk of gestational diabetes in singleton and twin pregnancies. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S197. NCT01812239 . Vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix. Double blind, placebo‐controlled, randomized clinical trial. clinicaltrials.gov/ct2/show/NCT01812239. NCT01812239 (first received 12 March 2013). "><b>Combs 2011</b> </a><b> twins</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0009" title="Hartikainen‐SorriAL , KauppilaA , TuimalaR . Inefficacy of 17alpha‐hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstetrics &amp; Gynecology1980;56:692‐5. Hartikainen‐SorriAL , KauppilaA , TuimalaR . Management of twin pregnancy with 17 alpha‐ hydroxyprogesterone caproate [abstract]. 9th World Congress of Gynecology and Obstetrics; 1979 October 26‐31; Tokyo, Japan. 1979:298‐9. "><b>Hartikainen‐Sorri 1980</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes in text</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0010" title="ISRCTN40512715 . 17‐alpha hydroxyprogesterone in multiple pregnancies to prevent handicapped infants. isrctn.com/ISRCTN40512715 (first received 2 November 2006). LimAC . The effect of 17‐alpha hydroxyprogesterone caproate on cervical length in multiple pregnancies. Reproductive Sciences2010;17(3 Suppl 1):282A. LimAC , BloemenkampKW , BoerK , DuvekotJJ , ErwichJJ , HasaartTH , et al. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial. BMC Pregnancy &amp; Childbirth2007;7:7. LimAC , SchuitE , BloemenkampK , BernardusRE , DuvekotJJ , ErwichJJ , et al. 17alpha‐hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: A randomized controlled trial. Obstetrics and Gynecology2011;118(3):513‐20. LimAC , SchuitE , PapatsonisD , VanEyckJ , PorathMM , VanOirschotCM , et al. Effect of 17‐alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound in Obstetrics &amp; Gynecology2012;40(4):426‐30. LimAC , for the Amphia Study Group. Is second trimester cervical length a predictor for an effect of 17‐alpha hydroxyprogesterone caproate on neonatal morbidity in multiple pregnancies? Results from the AMPHIA trial (ISRCTN40512715). Reproductive Sciences2010;17(3 Suppl 1):282A. MulderEJ , VersteeghEM , BloemenkampKW , LimAC , MolBW , BekedamDJ , et al. Does 17‐alpha‐hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?. Ultrasound in Obstetrics &amp; Gynecology2013;42(3):329‐34. WillekesC , LimA , VijgenS , MolB , PapatsonisD , HasaartT , et al. Mid‐pregnancy cervical length as a predictor of preterm birth in multiple pregnancies. American Journal of Obstetrics and Gynecology2011;204(1 Suppl):S54. "><b>Lim 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or more died during delivery after 24 wks and also any IUD before onset labour or onset delivery </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported “all live births”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No, and cannot be reliably added up from data presented</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0013" title="CaritisS , RouseD . A randomized controlled trial of 17‐hydroxyprogesterone caproate (17‐OHPC) for the prevention of preterm birth in twins. American Journal of Obstetrics and Gynecology2006;195(6 Suppl 1):S2. CaritisSN , SimhanH . Relationship of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) concentrations and gestational age at delivery in twins. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 139. CaritisSN , SimhanHN , ZhaoY , RouseDJ , PeacemanAM , SciscioneA , et al. Relationship between 17‐hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. American Journal of Obstetrics and Gynecology2012;207(5):396.e1‐396.e8. CaritisSN , VenkatR . Impact of body mass index (BMI) on plasma concentrations of 17‐alpha hydroxyprogesterone caproate (17‐OHPC). 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 138. DurnwaldC . The impact of cervical length on risk of preterm birth in twin gestations. American Journal of Obstetrics and Gynecology2008;199(6 Suppl 1):S10. DurnwaldCP , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , SciscioneA , et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17‐ hydroxyprogesterone caproate. Journal of Maternal‐Fetal and Neonatal Medicine2010;23(12):1360‐4. GyamfiC , HortonAL , MomirovaV , RouseDJ , CaritisSN , PeacemanAM , et al. The effect of 17‐alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies. American Journal of Obstetrics and Gynecology2009;201(4):392.e1‐5. RefuerzoJS , MomirovaV , PeacemanAM , SciscioneA , RouseDJ , CaritisSN , et al. Neonatal outcomes in twin pregnancies delivered moderately preterm, late preterm, and term. American Journal of Perinatology2010;27(7):537‐42. RouseDJ , CaritisSN , PeacemanAM , SciscioneA , ThomEA , SpongCY , et al. A trial of 17 alpha‐hydroxyprogesterone caproate to prevent prematurity in twins. New England Journal of Medicine2007;357(5):454‐61. SimhanHN , CaritisSN . The effect of 17‐alpha hydroxyprogesterone caproate (17‐OHPC) on maternal plasma CRP levels in twin pregnancies. 55th Annual Meeting of the Society of Gynecologic Investigation; 2008 March 26‐29; San Diego, USA2008:Abstract no: 140. "><b>Rouse 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, from text (not in table)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ‐ not sure why data not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0014" title="SenatMV , DeruelleP , WinerN , RozenbergP . Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(1 Suppl):S3. SenatMV , PorcherR , WinerN , VayssiereC , DeruelleP , CapelleM , et al. Prevention of preterm delivery by 17 alpha‐hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. American Journal of Obstetrics and Gynecology2013;208(3):194.e1‐194.e8. SenatMV , WinerN , PorcherR , RozenbergP . Prevention of preterm delivery in asymptomatic women with twin pregnancy by 17 alpha‐Hydroxyprogesterone caproate: a randomised controlled trial. Journal of Maternal‐Fetal and Neonatal Medicine2012;25(S2):14. "><b>Senat 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Can add NND and FD (IP and IU); all Ns clear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ‐ not sure why data not included</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes.</p> <p>Extrapolated from text and checked</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012024-bbs2-0005" title="CaritisSN , RouseDJ , PeacemanAM , SciscioneA , MomirovaV , SpongCY , et al. Prevention of preterm birth in triplets using 17 alpha‐hydroxyprogesterone caproate: a randomized controlled trial. Obstetrics &amp; Gynecology2009;113(2 Pt 1):285‐92. "><b>Caritis 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes, as a maternal outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cannot add FD and NND because FD reported as a maternal outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not included</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>IP: intrapartum<br/> IU: intra‐uterine<br/> IUD: intra‐uterine death<br/> N/A: not applicable<br/> wk: week </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reporting of fetal, neonatal and perinatal death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/full#CD012024-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012024-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intramuscular (IM) progesterone versus no treatment or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.06, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.06, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low dose (250 mg weekly or less)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.73, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High dose (greater than 250 mg weekly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.04, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth less than 34 week subgroup by timing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.06, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Commencing after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.04, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Mixed timing of commencement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.73, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Perinatal death subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low dose (250 mg weekly or less)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.48, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 High dose (greater than 250 mg weekly)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.11 [1.17, 71.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Perinatal death subgroup by timing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Starting before 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.34, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Starting after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.76 [0.81, 17.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed timing of start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.01, 37.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Prelabour rupture of the membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.84, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Preterm birth less than 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.75, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse drug reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.63, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.85, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.41, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.85, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Use of mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.36, 10.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.16, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.13, 27.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.36, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.39, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.44, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.13, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Patent ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.37, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Sensitivity analysis for perinatal death (assuming total dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1517</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.57, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Sensitivity analysis for perinatal death (assuming 1% dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.60, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intramuscular (IM) progesterone versus no treatment or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012024-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vaginal progesterone versus no treatment or placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 34 weeks subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low dose (200 mg or less daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.63, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High dose (more than 200 mg daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.40, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Preterm birth less than 34 weeks subgroup by timing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Starting before 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.30, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Starting after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Mixed timing of start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.90, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Perinatal death subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low dose (200 mg or less daily)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Perinatal death subgroup by timing <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Starting before 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.18, 21.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Starting after 20 weeks' gestation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.51, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mixed timing of start</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.63, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Prelabour rupture of the membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.20, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Preterm birth less than 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.79, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse drug reaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Satisfaction with therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.35, 0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Infant birthweight less than 2500 g <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Apgar score &lt; 7 at 5 minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.35, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.78, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Use of mechanical ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Intraventricular haemorrhage ‐ all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.62, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.45, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Necrotising enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.13, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.86, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Fetal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.65, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.75, 3.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Patent ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.47, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Sensitivity analysis for perinatal death (assuming total non‐independence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.61, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Sensitivity analysis for perinatal death (assuming 1% non‐independence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.74, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vaginal progesterone versus no treatment or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012024-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.04, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Perinatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.11 [1.17, 71.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prelabour rupture of the membranes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.63, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.90, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.88, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Antenatal tocolysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.76, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Antenatal corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.64, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Neonatal sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.03 [0.60, 42.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Respiratory distress syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.00, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.03 [0.46, 35.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Admission to NICU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.04, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Sensitivity analysis for perinatal death (assuming total dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.06 [0.60, 42.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis for perinatal death (assuming 1% dependence) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.11 [1.17, 71.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Intramuscular (IM) progesterone versus no treatment: multiple pregnancy and short cervix</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012024-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Vaginal progesterone versus placebo: multiple pregnancy and another risk factor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Preterm birth less than 34 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.29, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Preterm birth less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Vaginal progesterone versus placebo: multiple pregnancy and another risk factor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012024.pub3/references#CD012024-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012024.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012024-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012024-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012024-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ko#CD012024-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012024-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012024-note-0013">Português</a> </li> <li class="section-language"> <a class="" href="th#CD012024-note-0003">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012024\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012024\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012024\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012024\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012024\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012024.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012024.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012024.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012024.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012024.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715669274"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012024.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715669278"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012024.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8cbd1b2b9371',t:'MTc0MDcxNTY2OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 